1
|
Dupain C, Gutman T, Girard E, du Rusquec P, Sablin MP, Tresca P, Neuzillet C, Vincent-Salomon A, Antonio S, Franck C, Galut M, Allory Y, Cyrta J, Guillou I, Wong J, Le Tourneau C, Bièche I, Servant N, Kamal M, Masliah-Planchon J. 75P Tumor mutational burden in clinical routine practice: Identifying the right threshold? Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.355] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
2
|
de Guillebon E, Jimenez M, Mazzarella L, Betsou F, Stadler P, Peták I, Jeannot E, Chanas L, Servant N, Marret G, Duso BA, Legrand F, Kornerup KN, Bernhart SH, Balogh G, Dóczi R, Filotás P, Curigliano G, Bièche I, Guérin J, Dirner A, Neuzillet C, Girard N, Borcoman E, Larbi Chérif L, Tresca P, Roufai DB, Dupain C, Scholl S, André F, Fernandez X, Filleron T, Kamal M, Le Tourneau C. Combining immunotherapy with an epidrug in squamous cell carcinomas of different locations: rationale and design of the PEVO basket trial. ESMO Open 2021; 6:100106. [PMID: 33865192 PMCID: PMC8066350 DOI: 10.1016/j.esmoop.2021.100106] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2021] [Revised: 02/12/2021] [Accepted: 03/06/2021] [Indexed: 12/25/2022] Open
Abstract
Squamous cell carcinomas (SCCs) are among the most frequent solid tumors in humans. SCCs, related or not to the human papillomavirus, share common molecular features. Immunotherapies, and specifically immune checkpoint inhibitors, have been shown to improve overall survival in multiple cancer types, including SCCs. However, only a minority of patients experience a durable response with immunotherapy. Epigenetic modulation plays a major role in escaping tumor immunosurveillance and confers resistance to immune checkpoint inhibitors. Preclinical evidence suggests that modulating the epigenome might improve the efficacy of immunotherapy. We herein review the preclinical and the clinical rationale for combining immunotherapy with an epidrug, and detail the design of PEVOsq, a basket clinical trial combining pembrolizumab with vorinostat, a histone deacetylase inhibitor, in patients with SCCs of different locations. Sequential blood and tumor sampling will be collected in order to identify predictive and pharmacodynamics biomarkers of efficacy of the combination. We also present how clinical and biological data will be managed with the aim to enable the development of a prospective integrative platform to allow secure and controlled access to the project data as well as further exploitations.
Collapse
Affiliation(s)
- E de Guillebon
- Department of Drug Development and Innovation (D3i), Institut Curie, Paris, France; Inserm U932 Research Unit - Immunite et cancer, Paris, France
| | | | - L Mazzarella
- Department of Experimental Oncology, European Institute of Oncology - IRCCS, Milan, Italy; Division of Innovative Therapies, European Institute of Oncology - IRCCS, Milan, Italy
| | - F Betsou
- Integrated Biobank of Luxembourg, Dudelange, Luxembourg
| | - P Stadler
- Bioinformatics Group, Department of Computer, University of Leipzig, Leipzig, Germany
| | - I Peták
- Oncompass Medicine Ltd, Budapest, Hungary; Department of Pharmacology and Pharmacotherapy, Semmelweis University, Budapest, Hungary; Department of Pharmaceutical Sciences, University of Illinois at Chicago, Chicago, USA
| | - E Jeannot
- Department of Genetics, Institut Curie, Paris, France; Department of Pathology, Institut Curie, Paris, France
| | - L Chanas
- Data Direction, Institut Curie, Paris, France
| | - N Servant
- Inserm U900 Research Unit, Saint Cloud, France
| | - G Marret
- Department of Drug Development and Innovation (D3i), Institut Curie, Paris, France
| | - B A Duso
- Department of Experimental Oncology, European Institute of Oncology - IRCCS, Milan, Italy
| | | | - K N Kornerup
- Integrated Biobank of Luxembourg, Dudelange, Luxembourg
| | - S H Bernhart
- Bioinformatics Group, Department of Computer, University of Leipzig, Leipzig, Germany
| | - G Balogh
- Bioinformatics Group, Department of Computer, University of Leipzig, Leipzig, Germany
| | - R Dóczi
- Oncompass Medicine Ltd, Budapest, Hungary
| | - P Filotás
- Oncompass Medicine Ltd, Budapest, Hungary
| | - G Curigliano
- Division of Innovative Therapies, European Institute of Oncology - IRCCS, Milan, Italy; Department of Pharmacology and Pharmacotherapy, Semmelweis University, Budapest, Hungary; University of Milano, Milan, Italy
| | - I Bièche
- Department of Genetics, Institut Curie, Paris, France
| | - J Guérin
- Data Direction, Institut Curie, Paris, France
| | - A Dirner
- Oncompass Medicine Ltd, Budapest, Hungary
| | - C Neuzillet
- Department of Medical Oncology, Institut Curie, Paris, France; Paris-Saclay University, Paris, France
| | - N Girard
- Department of Medical Oncology, Institut Curie, Paris, France; Paris-Saclay University, Paris, France
| | - E Borcoman
- Department of Drug Development and Innovation (D3i), Institut Curie, Paris, France
| | - L Larbi Chérif
- Department of Drug Development and Innovation (D3i), Institut Curie, Paris, France
| | - P Tresca
- Department of Drug Development and Innovation (D3i), Institut Curie, Paris, France
| | - D B Roufai
- Department of Drug Development and Innovation (D3i), Institut Curie, Paris, France
| | - C Dupain
- Department of Drug Development and Innovation (D3i), Institut Curie, Paris, France
| | - S Scholl
- Department of Drug Development and Innovation (D3i), Institut Curie, Paris, France
| | - F André
- Department of Medical Oncology, Gustave Roussy, Villejuif; INSERM, Gustave Roussy Cancer Campus, UMR981, Villejuif; University of Paris-Sud, Orsay, France
| | - X Fernandez
- Data Direction, Institut Curie, Paris, France
| | - T Filleron
- Biostatistics Unit, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France
| | - M Kamal
- Department of Drug Development and Innovation (D3i), Institut Curie, Paris, France.
| | - C Le Tourneau
- Department of Drug Development and Innovation (D3i), Institut Curie, Paris, France; Inserm U900 Research Unit, Saint Cloud, France; Paris-Saclay University, Paris, France.
| |
Collapse
|
3
|
Cabel L, Bonneau C, Bernard-Tessier A, Héquet D, Tran-Perennou C, Bataillon G, Rouzier R, Féron JG, Fourchotte V, Le Brun JF, Benoît C, Rodrigues M, Scher N, Minsat M, Legrier ME, Bièche I, Proudhon C, Sastre-Garau X, Bidard FC, Jeannot E. HPV ctDNA detection of high-risk HPV types during chemoradiotherapy for locally advanced cervical cancer. ESMO Open 2021; 6:100154. [PMID: 34022731 PMCID: PMC8164037 DOI: 10.1016/j.esmoop.2021.100154] [Citation(s) in RCA: 27] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2021] [Revised: 03/26/2021] [Accepted: 04/20/2021] [Indexed: 01/12/2023] Open
Abstract
BACKGROUND Chemoradiotherapy (CRT) is the standard of care for patients diagnosed with locally advanced cervical cancer (LACC), a human papillomavirus (HPV)-related cancer that relapses in 30%-60% of patients. This study aimed to (i) design HPV droplet digital PCR (ddPCR) assays for blood detection (including rare genotypes) and (ii) monitor blood HPV circulating tumor DNA (HPV ctDNA) levels during CRT in patients with LACC. METHODS We analyzed blood and tumor samples from 55 patients with HPV-positive LACC treated by CRT in a retrospective cohort (n = 41) and a prospective cohort (n = 14). HPV-ctDNA detection was carried out by genotype-specific ddPCR. RESULTS HPV ctDNA was successfully detected in 69% of patients (n = 38/55) before CRT for LACC, including nine patients with a rare genotype. HPV-ctDNA level was correlated with HPV copy number in the tumor (r = 0.41, P < 0.001). HPV-ctDNA positivity for HPV18 (20%, n = 2/10) was significantly lower than for HPV16 (77%, n = 27/35) or other types (90%, n = 9/10, P = 0.002). HPV-ctDNA detection (positive versus negative) before CRT was associated with tumor stage (P = 0.037) and lymph node status (P = 0.02). Taking into account all samples from the end of CRT and during follow-up in the prospective cohort, positive HPV-ctDNA detection was associated with lower disease-free survival (DFS) (P = 0.048) and overall survival (OS) (P = 0.0013). CONCLUSION This is one of the largest studies to report HPV-ctDNA detection before CRT and showed clearance of HPV ctDNA at the end of treatment in most patients. Residual HPV ctDNA at the end of CRT or during follow-up could help to identify patients more likely to experience subsequent relapse.
Collapse
Affiliation(s)
- L Cabel
- Department of Medical Oncology, Institut Curie, Paris and Saint Cloud, France
| | - C Bonneau
- UVSQ, Paris-Saclay University, Gif-sur-Yvette, France; Department of Surgical Oncology, Institut Curie, Saint Cloud, France
| | - A Bernard-Tessier
- Department of Pathology and Genetics, Institut Curie, Paris and Saint Cloud, France
| | - D Héquet
- Department of Surgical Oncology, Institut Curie, Saint Cloud, France; U900, UVSQ, Paris-Saclay University, Gif-sur-Yvette, France
| | - C Tran-Perennou
- Department of Pathology and Genetics, Institut Curie, Paris and Saint Cloud, France
| | - G Bataillon
- Department of Pathology and Genetics, Institut Curie, Paris and Saint Cloud, France
| | - R Rouzier
- Department of Surgical Oncology, Institut Curie, Saint Cloud, France; U900, UVSQ, Paris-Saclay University, Gif-sur-Yvette, France
| | - J-G Féron
- Department of Surgical Oncology, Institut Curie, Saint Cloud, France
| | - V Fourchotte
- Department of Surgical Oncology, Institut Curie, Saint Cloud, France
| | - J-F Le Brun
- Department of Gynecology and Obstetrics, CCC François Baclesse, Caen, France
| | - C Benoît
- Department of Radiation Oncology, Centre Jean Perrin, Clermont-Ferrand, France
| | - M Rodrigues
- Department of Medical Oncology, Institut Curie, Paris and Saint Cloud, France
| | - N Scher
- Department of Radiation Oncology, Institut Curie, Paris and Saint Cloud, France
| | - M Minsat
- Department of Radiation Oncology, Institut Curie, Paris and Saint Cloud, France
| | - M-E Legrier
- Department of Research, Institut Curie, Paris and Saint Cloud, France
| | - I Bièche
- Department of Pathology and Genetics, Institut Curie, Paris and Saint Cloud, France; Paris University, Paris, France
| | - C Proudhon
- Circulating Tumor Biomarkers Laboratory, Institut Curie, Paris, France
| | - X Sastre-Garau
- Department of Pathology, Hôpital Intercommunal de Créteil, Créteil, France
| | - F-C Bidard
- Department of Medical Oncology, Institut Curie, Paris and Saint Cloud, France; UVSQ, Paris-Saclay University, Gif-sur-Yvette, France; Circulating Tumor Biomarkers Laboratory, Institut Curie, Paris, France
| | - E Jeannot
- Department of Pathology and Genetics, Institut Curie, Paris and Saint Cloud, France.
| |
Collapse
|
4
|
Mosele F, Remon J, Mateo J, Westphalen CB, Barlesi F, Lolkema MP, Normanno N, Scarpa A, Robson M, Meric-Bernstam F, Wagle N, Stenzinger A, Bonastre J, Bayle A, Michiels S, Bièche I, Rouleau E, Jezdic S, Douillard JY, Reis-Filho JS, Dienstmann R, André F. Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. Ann Oncol 2020; 31:1491-1505. [PMID: 32853681 DOI: 10.1016/j.annonc.2020.07.014] [Citation(s) in RCA: 563] [Impact Index Per Article: 140.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2020] [Accepted: 07/20/2020] [Indexed: 02/06/2023] Open
Abstract
Next-generation sequencing (NGS) allows sequencing of a high number of nucleotides in a short time frame at an affordable cost. While this technology has been widely implemented, there are no recommendations from scientific societies about its use in oncology practice. The European Society for Medical Oncology (ESMO) is proposing three levels of recommendations for the use of NGS. Based on the current evidence, ESMO recommends routine use of NGS on tumour samples in advanced non-squamous non-small-cell lung cancer (NSCLC), prostate cancers, ovarian cancers and cholangiocarcinoma. In these tumours, large multigene panels could be used if they add acceptable extra cost compared with small panels. In colon cancers, NGS could be an alternative to PCR. In addition, based on the KN158 trial and considering that patients with endometrial and small-cell lung cancers should have broad access to anti-programmed cell death 1 (anti-PD1) antibodies, it is recommended to test tumour mutational burden (TMB) in cervical cancers, well- and moderately-differentiated neuroendocrine tumours, salivary cancers, thyroid cancers and vulvar cancers, as TMB-high predicted response to pembrolizumab in these cancers. Outside the indications of multigene panels, and considering that the use of large panels of genes could lead to few clinically meaningful responders, ESMO acknowledges that a patient and a doctor could decide together to order a large panel of genes, pending no extra cost for the public health care system and if the patient is informed about the low likelihood of benefit. ESMO recommends that the use of off-label drugs matched to genomics is done only if an access programme and a procedure of decision has been developed at the national or regional level. Finally, ESMO recommends that clinical research centres develop multigene sequencing as a tool to screen patients eligible for clinical trials and to accelerate drug development, and prospectively capture the data that could further inform how to optimise the use of this technology.
Collapse
Affiliation(s)
- F Mosele
- Department of Medical Oncology, Gustave Roussy, Villejuif, France
| | - J Remon
- Department of Medical Oncology, Centro Integral Oncológico Clara Campal (HM-CIOCC), Hospital HM Delfos, HM Hospitales, Barcelona, Spain
| | - J Mateo
- Clinical Research Program, Vall Hebron Institute of Oncology (VHIO) and Vall d'Hebron University Hospital, Barcelona, Spain
| | - C B Westphalen
- Comprehensive Cancer Center Munich and Department of Medicine III, University Hospital, LMU Munich, Munich, Germany
| | - F Barlesi
- Department of Medical Oncology, Gustave Roussy, Villejuif, France
| | - M P Lolkema
- Department of Medical Oncology, Erasmus MC Cancer Center, Rotterdam, the Netherlands
| | - N Normanno
- Cell Biology and Biotherapy Unit, Istituto Nazionale Tumori, 'Fondazione G. Pascale' - IRCCS, Naples, Italy
| | - A Scarpa
- ARC-Net Research Centre and Department of Diagnostics and Public Health - Section of Pathology, University of Verona, Verona, Italy
| | - M Robson
- Breast Medicine and Clinical Genetics Services, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA
| | - F Meric-Bernstam
- Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, USA
| | - N Wagle
- Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, USA
| | - A Stenzinger
- Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany
| | - J Bonastre
- Department of Biostatistics and Epidemiology, Gustave Roussy, University Paris-Saclay, Villejuif, France; Oncostat U1018, Inserm, University Paris-Saclay, labeled Ligue Contre le Cancer, Villejuif, France
| | - A Bayle
- Department of Medical Oncology, Gustave Roussy, Villejuif, France; Department of Biostatistics and Epidemiology, Gustave Roussy, University Paris-Saclay, Villejuif, France; Oncostat U1018, Inserm, University Paris-Saclay, labeled Ligue Contre le Cancer, Villejuif, France
| | - S Michiels
- Department of Biostatistics and Epidemiology, Gustave Roussy, University Paris-Saclay, Villejuif, France; Oncostat U1018, Inserm, University Paris-Saclay, labeled Ligue Contre le Cancer, Villejuif, France
| | - I Bièche
- Department of Genetics, Institut Curie, Paris Descartes University, Paris, France
| | - E Rouleau
- Cancer Genetic Laboratories, Department of Medical Biology and Pathology, Gustave Roussy Cancer Campus, Villejuif, France
| | - S Jezdic
- Scientific and Medical Division, European Society for Medical Oncology, Lugano, Switzerland
| | - J-Y Douillard
- Scientific and Medical Division, European Society for Medical Oncology, Lugano, Switzerland
| | - J S Reis-Filho
- Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, USA
| | - R Dienstmann
- Oncology Data Science Group, Molecular Prescreening Program, Vall d'Hebron Institute of Oncology, Barcelona, Spain
| | - F André
- Department of Medical Oncology, Gustave Roussy, Villejuif, France; Inserm, Gustave Roussy Cancer Campus, UMR981, Villejuif, France; Paris Saclay University, Orsay, France.
| |
Collapse
|
5
|
Mosele F, Stefanovska B, Lusque A, Tran Dien A, Garberis I, Droin N, Le Tourneau C, Sablin MP, Lacroix L, Enrico D, Miran I, Jovelet C, Bièche I, Soria JC, Bertucci F, Bonnefoi H, Campone M, Dalenc F, Bachelot T, Jacquet A, Jimenez M, André F. Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer. Ann Oncol 2020; 31:377-386. [PMID: 32067679 DOI: 10.1016/j.annonc.2019.11.006] [Citation(s) in RCA: 139] [Impact Index Per Article: 34.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2019] [Revised: 10/15/2019] [Accepted: 11/04/2019] [Indexed: 01/04/2023] Open
Abstract
BACKGROUND α-Selective phosphatidylinositol 3-kinase (PI3K) inhibitors improve outcome in patients with PIK3CA-mutated, hormone receptor-positive (HR+)/Her2- metastatic breast cancer (mBC). Nevertheless, it is still unclear how to integrate this new drug family in the treatment landscape. PATIENTS AND METHODS A total of 649 patients with mBC from the SAFIR02 trial (NCT02299999), with available mutational profiles were selected for outcome analysis. PIK3CA mutations were prospectively determined by next-generation sequencing on metastatic samples. The mutational landscape of PIK3CA-mutated mBC was assessed by whole-exome sequencing (n = 617). Finally, the prognostic value of PIK3CA mutations during chemotherapy was assessed in plasma samples (n = 44) by next-generation sequencing and digital PCR. RESULTS Some 28% (104/364) of HR+/Her2- tumors and 10% (27/255) of triple-negative breast cancer (TNBC) presented a PIK3CA mutation (P < 0.001). PIK3CA-mutated HR+/Her2- mBC was less sensitive to chemotherapy [adjusted odds ratio: 0.40; 95% confidence interval (0.22-0.71); P = 0.002], and presented a worse overall survival (OS) compared with PIK3CA wild-type [adjusted hazard ratio: 1.44; 95% confidence interval (1.02-2.03); P = 0.04]. PIK3CA-mutated HR+/Her2- mBC was enriched in MAP3K1 mutations (15% versus 5%, P = 0.0005). In metastatic TNBC (mTNBC), the median OS in patients with PIK3CA mutation was 24 versus 14 months for PIK3CA wild-type (P = 0.03). We further looked at the distribution of PIK3CA mutation in mTNBC according to HR expression on the primary tumor. Some 6% (9/138) of patients without HR expression on the primary and 36% (14/39) of patients with HR+ on the primary presented PIK3CA mutation (P < 0.001). The level of residual PIK3CA mutations in plasma after one to three cycles of chemotherapy was associated with a poor OS [continuous variable, hazard ratio: 1.03, 95% confidence interval (1.01-1.05), P = 0.007]. CONCLUSION PIK3CA-mutated HR+/Her2- mBC patients present a poor outcome and resistance to chemotherapy. Patients with PIK3CA-mutated TNBC present a better OS. This could be explained by an enrichment of PIK3CA mutations in luminal BC which lost HR expression in the metastatic setting. TRIAL REGISTRATION SAFIR02 trial: NCT02299999.
Collapse
Affiliation(s)
- F Mosele
- Department of Medical Oncology, Gustave Roussy, Villejuif, France
| | - B Stefanovska
- INSERM, Gustave Roussy Cancer Campus, UMR981, Villejuif, France
| | - A Lusque
- Institut Claudius Regaud, IUCT-O, Toulouse, France
| | - A Tran Dien
- Bioinformatics Platform, Gustave Roussy, Villejuif, France
| | - I Garberis
- INSERM, Gustave Roussy Cancer Campus, UMR981, Villejuif, France; Paris-Saclay University, Paris, France
| | - N Droin
- Genomic Core Facility UMS AMMICA Gustave Roussy, Villejuif, France
| | - C Le Tourneau
- Department of Drug Development and Innovation, Institut Curie, Paris, France; INSERM U900, Saint-Cloud, France; Paris-Saclay University, Paris, France
| | - M-P Sablin
- Department of Medical Oncology, Institut Curie, Paris, France
| | - L Lacroix
- Department of Medical Biology and Pathology, Gustave Roussy, Villejuif, France; Genomic Platform and Biobank, CNRS UMS3655-INSERM US23, AMMICA, Gustave Roussy, F-94805, Villejuif, France
| | - D Enrico
- Department of Medical Oncology, Gustave Roussy, Villejuif, France
| | - I Miran
- Genomic Platform and Biobank, CNRS UMS3655-INSERM US23, AMMICA, Gustave Roussy, F-94805, Villejuif, France
| | - C Jovelet
- Genomic Platform and Biobank, CNRS UMS3655-INSERM US23, AMMICA, Gustave Roussy, F-94805, Villejuif, France
| | - I Bièche
- Department of Genetics, Institut Curie, Paris, France; INSERM U1016, Paris Descartes University, Paris, France
| | - J-C Soria
- University of Paris-Sud, Orsay, France
| | - F Bertucci
- CRCM, Predictive Oncology team, Aix-Marseille University, CNRS, INSERM, Institut Paoli-Calmettes, Marseille, France
| | - H Bonnefoi
- Department of Medical Oncology, Institut Bergonie, Bordeaux, France
| | - M Campone
- Department of Medical Oncology, Institut of Cancerology Ouest, Nantes, France
| | - F Dalenc
- Institut Claudius Regaud, IUCT-O, Toulouse, France
| | - T Bachelot
- Department of Medical Oncology, Center Leon Berard, Lyon, France
| | - A Jacquet
- Precision Medicine Group, UNICANCER, Paris, France
| | - M Jimenez
- Precision Medicine Group, UNICANCER, Paris, France
| | - F André
- Department of Medical Oncology, Gustave Roussy, Villejuif, France; INSERM, Gustave Roussy Cancer Campus, UMR981, Villejuif, France; University of Paris-Sud, Orsay, France.
| |
Collapse
|
6
|
Blandinières A, Gille T, Sadoine J, Bièche I, Slimani L, Dizier B, Gaussem P, Chaussain C, Planes C, Dorfmuller P, Israel-Biet D, Smadja D. Les progéniteurs endothéliaux circulants ne participent pas à la fibrogenèse dans le modèle de fibrose pulmonaire induite par la bléomycine chez la souris Nude. Rev Mal Respir 2019. [DOI: 10.1016/j.rmr.2018.10.093] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
7
|
Bonsang B, Bièche I, Pasmant E, Laurendeau I, Maksimovic L, Martin N, Wolkenstein P, Ortonne N. Expression des isoformes du VEGF et de son récepteur dans les tumeurs nerveuses de neurofibromatose de type 1 : une nouvelle voie d’oncogenèse par stimulation autocrine et paracrine ? Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.230] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
8
|
Remon J, Rouleau E, Barlesi F, Leary A, Bièche I, Job B, Lacroix L, Auguste A, Mauduit M, Audigier-Valette C, Raimbourg J, Madroszyk A, Michiels S, Bayar M, Jimenez M, Soria J, Besse B. P3.03-27 Somatic BRCA1/2 Mutations in Advanced NSCLC Patients: Description of a Sub-Population from the Ongoing Unicancer SAFIR02-Lung / IFCT-1301 Trial. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.1704] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
9
|
Vassal G, Cozic N, Houot R, Brugières L, Aparicio T, Blay JY, Perol M, Brice P, Meriaux E, Geoerger B, El Bejjani M, Moalla S, Bièche I, Lantuejoul S, Mahier Ait Oukhatar C, Hoog Labouret N, Moro-Sibilot D. Biomarker-driven access to crizotinib in ALK, MET or ROS1 positive (+) malignancies in adults and children: The French national AcSé program. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy279.421] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
10
|
Bernard-Tessier A, Jeannot E, Guenat D, Michel M, Proudhon C, Vincent-Salomon A, Bièche I, Pierga JY, Buecher B, Francois E, Kim S, André T, Jary M, Vendrely V, Samalin E, El Hajbi F, Baba-Hamed N, Meurisse A, Bidard FC, Borg C. HPV circulating tumor DNA as predictive biomarker of sustained response to chemotherapy in advanced anal carcinoma. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy269.092] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
11
|
Spyratos F, Andrieu C, Vidaud D, Briffod M, Vidaud M, Lidereau R, Bièche I. CCND1 mRNA Overexpression is Highly Related to Estrogen Receptor Positivity but not to Proliferative Markers in Primary Breast Cancer. Int J Biol Markers 2018. [DOI: 10.1177/172460080001500301] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
To elucidate the role of CCND1 alterations in sporadic breast cancer we investigated the possible link between CCND1 mRNA levels versus estrogen-receptor (ER) status and a proliferation marker, S-phase fraction (SPF), measured by flow cytometry. CCND1 expression was quantified by means of real-time quantitative RT-PCR in a well-characterized series of 33 primary breast cancer patients. Eighteen tumors (54.5%) showed CCND1 overexpression ranging from 3.3 to 29.5 times the level observed in normal breast tissue. Seventeen (94.4%) of the 18 cases with CCND1 overexpression were ER-positive compared to seven (46.7%) of the 15 cases with normal CCND1 expression (p=0.0074). CCND1 overexpression was independent of SPF and DNA-ploidy status. These data suggest that the CCND1 gene does not act as an oncogene responsible for more rapid cell proliferation in breast cancer, but could be involved in the regulation of hormone sensitivity associated with ER.
Collapse
Affiliation(s)
- F. Spyratos
- Département d'Anatomo-cytopathologie Faculté des Sciences Pharmaceutiques et Biologiques de Paris - France
- Centre René Huguenin, Saint-Cloud
| | - C. Andrieu
- Laboratoire d'Oncobiologie Faculté des Sciences Pharmaceutiques et Biologiques de Paris - France
- Laboratoire de Génétique Moléculaire
- Centre René Huguenin, Saint-Cloud
| | - D. Vidaud
- Département d'Anatomo-cytopathologie Faculté des Sciences Pharmaceutiques et Biologiques de Paris - France
- Centre René Huguenin, Saint-Cloud
| | - M. Briffod
- Laboratoire d'Oncogénétique Faculté des Sciences Pharmaceutiques et Biologiques de Paris - France
- Centre René Huguenin, Saint-Cloud
| | - M. Vidaud
- Département d'Anatomo-cytopathologie Faculté des Sciences Pharmaceutiques et Biologiques de Paris - France
- Centre René Huguenin, Saint-Cloud
| | - R. Lidereau
- Laboratoire de Génétique Moléculaire
- Centre René Huguenin, Saint-Cloud
| | - I. Bièche
- Département d'Anatomo-cytopathologie Faculté des Sciences Pharmaceutiques et Biologiques de Paris - France
- Laboratoire de Génétique Moléculaire
- Centre René Huguenin, Saint-Cloud
| |
Collapse
|
12
|
Abstract
The GSTT1 and GSTM1 genes are characterized by the existence of a GST*0 null allele responsible for a lack of enzyme activity, with the respective null genotypes GSTT1*0/0 and GSTM1*0/0. The three resulting genotypes (GSTs*1/1, *1/0 and *0/0) are associated with a trimodal distribution of glutathione-conjugator activity. Previous epidemiological studies have only evaluated the cancer risk associated with the GST null genotype relative to the two GST carrier geno-® types (GSTs1*1/1 and *1/0). We developed GSTT1 and GSTM1 TaqMan real-time quantitative PCR assays to discriminate each of the three genotypes, with the albumin gene (ALB) as reference. The mean NGSTT1*1/1 value was 1.0 (95% confidence interval 0.80–1.20). The mean NGSTT1*1/0 value was 0.48 (95% CI 0.36–0.60). One (3.4%) of the 29 DNA samples yielded the GSTM1*1/1 genotype (NGSTM1*1/1 = 1), a frequency in keeping with the Hardy-Weinberg distribution. The mean NGSTM1*1/0 value was 0.50 (95% CI 0.42–0.58). All GSTT1*0/0 and GSTM1*0/0 samples yielded NGST values of 0 (Ct = 40); the frequencies of these genotypes (27.6% and 55.2%, respectively) were in keeping with published data. The GSTT1 and GSTM1 real-time PCR assays described here unambiguously discriminate each of the three existing genotypes which should be valuable for assessing the relative risk of cancer associated with each of the three GST genotypes.
Collapse
Affiliation(s)
- I. Girault
- Laboratoire d'Oncogénétique, INSERM
U735, Centre René Huguenin, St-Cloud
| | - R. Lidereau
- Laboratoire d'Oncogénétique, INSERM
U735, Centre René Huguenin, St-Cloud
| | - I. Bièche
- Laboratoire d'Oncogénétique, INSERM
U735, Centre René Huguenin, St-Cloud
- Laboratoire de Génétique Moléculaire,
UPRES EA 3618, Faculté des Sciences Pharmaceutiques et Biologiques, Université René
Descartes, Paris - France
| |
Collapse
|
13
|
Dos Santos ES, Caputo SM, Castera L, Gendrot M, Briaux A, Breault M, Krieger S, Rogan PK, Mucaki EJ, Burke LJ, Bièche I, Houdayer C, Vaur D, Stoppa-Lyonnet D, Brown MA, Lallemand F, Rouleau E. Assessment of the functional impact of germline BRCA1/2 variants located in non-coding regions in families with breast and/or ovarian cancer predisposition. Breast Cancer Res Treat 2017; 168:311-325. [PMID: 29236234 DOI: 10.1007/s10549-017-4602-0] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2017] [Accepted: 11/28/2017] [Indexed: 12/19/2022]
Abstract
PURPOSE The molecular mechanism of breast and/or ovarian cancer susceptibility remains unclear in the majority of patients. While germline mutations in the regulatory non-coding regions of BRCA1 and BRCA2 genes have been described, screening has generally been limited to coding regions. The aim of this study was to evaluate the contribution of BRCA1/2 non-coding variants. METHODS Four BRCA1/2 non-coding regions were screened using high-resolution melting analysis/Sanger sequencing or next-generation sequencing on DNA extracted from index cases with breast and ovarian cancer predisposition (3926 for BRCA1 and 3910 for BRCA2). The impact of a set of variants on BRCA1/2 gene regulation was evaluated by site-directed mutagenesis, transfection, followed by Luciferase gene reporter assay. RESULTS We identified a total of 117 variants and tested twelve BRCA1 and 8 BRCA2 variants mapping to promoter and intronic regions. We highlighted two neighboring BRCA1 promoter variants (c.-130del; c.-125C > T) and one BRCA2 promoter variants (c.-296C > T) inhibiting significantly the promoter activity. In the functional assays, a regulating region within the intron 12 was found with the same enhancing impact as within the intron 2. Furthermore, the variants c.81-3980A > G and c.4186-2022C > T suppress the positive effect of the introns 2 and 12, respectively, on the BRCA1 promoter activity. We also found some variants inducing the promoter activities. CONCLUSION In this study, we highlighted some variants among many, modulating negatively the promoter activity of BRCA1 or 2 and thus having a potential impact on the risk of developing cancer. This selection makes it possible to conduct future validation studies on a limited number of variants.
Collapse
Affiliation(s)
- E Santana Dos Santos
- Department of Oncology, Center for Translational Oncology, Cancer Institute of the State of São Paulo - ICESP, São Paulo, Brazil
- Service de Génétique, Institut Curie, Paris, France
- A.C.Camargo Cancer Center, São Paulo, Brazil
| | - S M Caputo
- Service de Génétique, Institut Curie, Paris, France
| | - L Castera
- Laboratoire de Biologie et de Génétique du Cancer, CLCC François Baclesse, INSERM 1079 Centre Normand de Génomique et de MédecinePersonnalisée, Caen, France
| | - M Gendrot
- Service de Génétique, Institut Curie, Paris, France
| | - A Briaux
- Service de Génétique, Institut Curie, Paris, France
| | - M Breault
- Service de Génétique, Institut Curie, Paris, France
| | - S Krieger
- Laboratoire de Biologie et de Génétique du Cancer, CLCC François Baclesse, INSERM 1079 Centre Normand de Génomique et de MédecinePersonnalisée, Caen, France
| | - P K Rogan
- Department of Biochemistry, Schulich School of Medicine and Dentistry, University of Western Ontario, London, Canada
| | - E J Mucaki
- Department of Biochemistry, Schulich School of Medicine and Dentistry, University of Western Ontario, London, Canada
| | - L J Burke
- School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, Australia
| | - I Bièche
- Service de Génétique, Institut Curie, Paris, France
- Université Paris Descartes, Paris, France
| | - C Houdayer
- Service de Génétique, Institut Curie, Paris, France
- Université Paris Descartes, Paris, France
| | - D Vaur
- Laboratoire de Biologie et de Génétique du Cancer, CLCC François Baclesse, INSERM 1079 Centre Normand de Génomique et de MédecinePersonnalisée, Caen, France
| | - D Stoppa-Lyonnet
- Service de Génétique, Institut Curie, Paris, France
- Université Paris Descartes, Paris, France
| | - M A Brown
- School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, Australia
| | - F Lallemand
- Service de Génétique, Institut Curie, Paris, France.
| | | |
Collapse
|
14
|
Coussy F, Lallemand F, Vacher S, Schnitzler A, Chemlali W, Caly M, Nicolas A, Richon S, Meseure D, El Botty R, De-Plater L, Fuhrmann L, Dubois T, Roman-Roman S, Dangles-Marie V, Marangoni E, Bièche I. Clinical value of R-spondins in triple-negative and metaplastic breast cancers. Br J Cancer 2017; 116:1595-1603. [PMID: 28472820 PMCID: PMC5518860 DOI: 10.1038/bjc.2017.131] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2016] [Revised: 04/07/2017] [Accepted: 04/13/2017] [Indexed: 01/08/2023] Open
Abstract
Background: RSPO ligands, activators of the Wnt/β-catenin pathway, are overexpressed in different cancers. The objective of this study was to investigate the role of RSPOs in breast cancer (BC). Methods: Expression of RSPO and markers of various cancer pathways were measured in breast tumours and cell lines by qRT–PCR. The effect of RSPO on the Wnt/β-catenin pathway activity was determined by luciferase assay, western blotting, and qRT–PCR. The effect of RSPO2 inhibition on proliferation was determined by using RSPO2 siRNAs. The effect of IWR-1, an inhibitor of the Wnt/β-catenin pathway, was examined on the growth of an RSPO2-positive patient-derived xenograft (PDX) model of metaplastic triple-negative BC. Results: We detected RSPO2 and RSPO4 overexpression levels in BC, particularly in triple-negative BC (TNBC), metaplastic BC, and triple-negative cell lines. Various mechanisms could account for this overexpression: presence of fusion transcripts involving RSPO, and amplification or hypomethylation of RSPO genes. Patients with RSPO2-overexpressing tumours have a poorer metastasis-free survival (P=3.6 × 10−4). RSPO2 and RSPO4 stimulate Wnt/β-catenin pathway activity. Inhibition of RSPO expression in a TN cell line inhibits cell growth, and IWR-1 significantly inhibits the growth of an RSPO2-overexpressing PDX. Conclusions: RSPO overexpression could therefore be a new prognostic biomarker and therapeutic target for TNBC.
Collapse
Affiliation(s)
- F Coussy
- Unit of pharmacogenomics, Department of Genetics, Institut Curie, 26 rue d'Ulm, Paris 75005, France
| | - F Lallemand
- Unit of pharmacogenomics, Department of Genetics, Institut Curie, 26 rue d'Ulm, Paris 75005, France
| | - S Vacher
- Unit of pharmacogenomics, Department of Genetics, Institut Curie, 26 rue d'Ulm, Paris 75005, France
| | - A Schnitzler
- Unit of pharmacogenomics, Department of Genetics, Institut Curie, 26 rue d'Ulm, Paris 75005, France
| | - W Chemlali
- Unit of pharmacogenomics, Department of Genetics, Institut Curie, 26 rue d'Ulm, Paris 75005, France
| | - M Caly
- Department of Biopathology, Institut Curie, 26 rue d'Ulm, Paris 75005, France
| | - A Nicolas
- Department of Biopathology, Institut Curie, 26 rue d'Ulm, Paris 75005, France
| | - S Richon
- CNRS, UMR 144, Research Center, Institut Curie, 26 rue d'Ulm, Paris 75005, France
| | - D Meseure
- Department of Biopathology, Institut Curie, 26 rue d'Ulm, Paris 75005, France
| | - R El Botty
- Laboratory of Preclinical Investigation, Department of Translational Research, Institut Curie, 26 rue d'Ulm, Paris 75005, France
| | - L De-Plater
- Laboratory of Preclinical Investigation, Department of Translational Research, Institut Curie, 26 rue d'Ulm, Paris 75005, France
| | - L Fuhrmann
- Department of Biopathology, Institut Curie, 26 rue d'Ulm, Paris 75005, France
| | - T Dubois
- Breast Cancer Biology Group, Department of Translational Research, Institut Curie, 26 rue d'Ulm, Paris 75005, France
| | - S Roman-Roman
- Department of Translational Research, Institut Curie, 26 rue d'Ulm, Paris 75005, France
| | - V Dangles-Marie
- Laboratory of Preclinical Investigation, Department of Translational Research, Institut Curie, 26 rue d'Ulm, Paris 75005, France.,Université Paris Descartes, Sorbonne Paris Cité, Paris 75006, France
| | - E Marangoni
- Laboratory of Preclinical Investigation, Department of Translational Research, Institut Curie, 26 rue d'Ulm, Paris 75005, France
| | - I Bièche
- Unit of pharmacogenomics, Department of Genetics, Institut Curie, 26 rue d'Ulm, Paris 75005, France.,EA7331, University Paris Descartes, 4 avenue de l'observatoire, Paris 75006, France
| |
Collapse
|
15
|
Gonçalves A, Bachelot T, Lusque A, Arnedos M, Campone M, Bièche I, Lacroix L, Pierron G, Dalenc F, Filleron T, Sablin MP, Jimenez M, Ferrero JM, Lefeuvre-Plesse C, Bonnefoi H, Attignon V, Soubeyran I, Jezequel P, Commo F, André F. Abstract PD1-08: High-throughput genome analysis and therapeutic decision for patients with HER2-negative metastatic breast cancer: First feasibility and molecular results of the randomized phase II study SAFIR02 BREAST (UCBG-0105/1304). Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-pd1-08] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background A genomic-driven therapeutic strategy in metastatic breast cancer (MBC) was recently demonstrated as feasible in the clinical practice, but its actual impact on patient outcome remains elusive. SAFIR02 study is an ongoing national multicentric phase II randomized trial evaluating targeted therapies matching specific genomic alterations (GA) administered as maintenance after objective response and/or stable disease obtained with chemotherapy in HER2-negative MBC patients. This analysis reports on feasibility of the procedure and the rate of identified actionable targets.
Methods Eligible MBC patients (PS=0/1, first- or second-line of chemotherapy, HER2-negative/hormone receptor (HR)-negative or endocrine resistant HR-positive; measurable per RECIST 1.1; accessible to tumor biopsy; no bone metastases-only disease, no major organ dysfunction) were subjected to tumor biopsy for genomic analysis (CGH arrays, Affymetrix Cytoscan; NGS, Ion Torrent PGM, AmpliSeq, panel of around 50 genes). Actionable GA were identified and corresponding targeted therapies were proposed by a multidisciplinary tumor board (MTB). Patients received cytotoxic-based treatment at physician's choice and those with stable or responding disease after 6 to 8 cycles (or at least 4 if stopped for toxicity reason) and targetable GA, were offered randomization between targeted therapy or chemotherapy maintenance until progression or intolerance (main study). Since January 2016, an amendment was made to propose to patients without targetable alteration a randomization between anti-PD-L1 (MEDI4736) or standard chemotherapy maintenance (substudy).
Results Between March 2014 and May 2016, 457 patients have been enrolled at 21 centers. Genomic analyses could not be obtained in 107 cases (23%) due to either biopsy failure (n= 40; 9%) or low cellularity (n=67; 14%). Of the 307 patients reviewed by the MTB, 197 (64%) had an actionable GA, including PIK3CA-PIK3CB-PIK3R1 (n=51), FGF4 or FGFR1/2 (n= 42), BRCA1/2 (n=15), AKT1/2/3 (n=13), BRAF/KRAS/NRAS (n=13), HER2/3 (n=10), NF1-FRS2 (n=10), MTOR-RPTOR-TSC2 (n=8), PTEN (n=7), STK11 (n=7), IGF1R (n=7), EGFR (n=5). Therapeutic proposals by MTB included AZD5363 (n=71), AZD4547 (n=42), AZD2014 (n=23), selumetinib (n=23), olaparib (n=16), AZD8931 (n=15), vandetanib (n=5), bicalutamide (n=2). In an exploratory analysis involving 157 patients, the rate of targeted therapy proposal by MTB markedly differed between triple-negative patients (TNBC; 24 of 48, 50%) and HER2-negative/HR-positive patients (92 of 109, 84%; p=6.14. 10-6, Chi-2 test). At the time of the analysis, 85 patients have been randomized (main study, 68; substudy, 17). Causes of randomization failure (n=108) included disease progression (n=45) or death (n=25), non-eligibility criteria (n=27), patient/physician's decision (n=11).
Conclusion A large number of patients had identified targetable GA. Of note, the rate of targeted therapeutic proposal was significantly lower in TNBC than in HER2-negative/HR-positive patients. Rapidly progressing disease may impede ultimate randomization.
Citation Format: Gonçalves A, Bachelot T, Lusque A, Arnedos M, Campone M, Bièche I, Lacroix L, Pierron G, Dalenc F, Filleron T, Sablin M-P, Jimenez M, Ferrero J-M, Lefeuvre-Plesse C, Bonnefoi H, Attignon V, Soubeyran I, Jezequel P, Commo F, André F. High-throughput genome analysis and therapeutic decision for patients with HER2-negative metastatic breast cancer: First feasibility and molecular results of the randomized phase II study SAFIR02 BREAST (UCBG-0105/1304) [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr PD1-08.
Collapse
Affiliation(s)
- A Gonçalves
- Institut Paoli Calmettes, Marseille, France; Centre Léon Bérard, Lyon, France; Institut Claudius Regaud- IUCT-O, Toulouse, France; Gustave Roussy Cancer Campus, Villejuif, France; Institut de Cancérologie de l'Ouest, Nantes, France; Institut Curie, Paris, France; Unicancer, Paris, France; Centre Antoine Lacassagne, Nice, France; Centre Eugène Marquis, Rennes, France; Institut Bergonié, Bordeaux, France
| | - T Bachelot
- Institut Paoli Calmettes, Marseille, France; Centre Léon Bérard, Lyon, France; Institut Claudius Regaud- IUCT-O, Toulouse, France; Gustave Roussy Cancer Campus, Villejuif, France; Institut de Cancérologie de l'Ouest, Nantes, France; Institut Curie, Paris, France; Unicancer, Paris, France; Centre Antoine Lacassagne, Nice, France; Centre Eugène Marquis, Rennes, France; Institut Bergonié, Bordeaux, France
| | - A Lusque
- Institut Paoli Calmettes, Marseille, France; Centre Léon Bérard, Lyon, France; Institut Claudius Regaud- IUCT-O, Toulouse, France; Gustave Roussy Cancer Campus, Villejuif, France; Institut de Cancérologie de l'Ouest, Nantes, France; Institut Curie, Paris, France; Unicancer, Paris, France; Centre Antoine Lacassagne, Nice, France; Centre Eugène Marquis, Rennes, France; Institut Bergonié, Bordeaux, France
| | - M Arnedos
- Institut Paoli Calmettes, Marseille, France; Centre Léon Bérard, Lyon, France; Institut Claudius Regaud- IUCT-O, Toulouse, France; Gustave Roussy Cancer Campus, Villejuif, France; Institut de Cancérologie de l'Ouest, Nantes, France; Institut Curie, Paris, France; Unicancer, Paris, France; Centre Antoine Lacassagne, Nice, France; Centre Eugène Marquis, Rennes, France; Institut Bergonié, Bordeaux, France
| | - M Campone
- Institut Paoli Calmettes, Marseille, France; Centre Léon Bérard, Lyon, France; Institut Claudius Regaud- IUCT-O, Toulouse, France; Gustave Roussy Cancer Campus, Villejuif, France; Institut de Cancérologie de l'Ouest, Nantes, France; Institut Curie, Paris, France; Unicancer, Paris, France; Centre Antoine Lacassagne, Nice, France; Centre Eugène Marquis, Rennes, France; Institut Bergonié, Bordeaux, France
| | - I Bièche
- Institut Paoli Calmettes, Marseille, France; Centre Léon Bérard, Lyon, France; Institut Claudius Regaud- IUCT-O, Toulouse, France; Gustave Roussy Cancer Campus, Villejuif, France; Institut de Cancérologie de l'Ouest, Nantes, France; Institut Curie, Paris, France; Unicancer, Paris, France; Centre Antoine Lacassagne, Nice, France; Centre Eugène Marquis, Rennes, France; Institut Bergonié, Bordeaux, France
| | - L Lacroix
- Institut Paoli Calmettes, Marseille, France; Centre Léon Bérard, Lyon, France; Institut Claudius Regaud- IUCT-O, Toulouse, France; Gustave Roussy Cancer Campus, Villejuif, France; Institut de Cancérologie de l'Ouest, Nantes, France; Institut Curie, Paris, France; Unicancer, Paris, France; Centre Antoine Lacassagne, Nice, France; Centre Eugène Marquis, Rennes, France; Institut Bergonié, Bordeaux, France
| | - G Pierron
- Institut Paoli Calmettes, Marseille, France; Centre Léon Bérard, Lyon, France; Institut Claudius Regaud- IUCT-O, Toulouse, France; Gustave Roussy Cancer Campus, Villejuif, France; Institut de Cancérologie de l'Ouest, Nantes, France; Institut Curie, Paris, France; Unicancer, Paris, France; Centre Antoine Lacassagne, Nice, France; Centre Eugène Marquis, Rennes, France; Institut Bergonié, Bordeaux, France
| | - F Dalenc
- Institut Paoli Calmettes, Marseille, France; Centre Léon Bérard, Lyon, France; Institut Claudius Regaud- IUCT-O, Toulouse, France; Gustave Roussy Cancer Campus, Villejuif, France; Institut de Cancérologie de l'Ouest, Nantes, France; Institut Curie, Paris, France; Unicancer, Paris, France; Centre Antoine Lacassagne, Nice, France; Centre Eugène Marquis, Rennes, France; Institut Bergonié, Bordeaux, France
| | - T Filleron
- Institut Paoli Calmettes, Marseille, France; Centre Léon Bérard, Lyon, France; Institut Claudius Regaud- IUCT-O, Toulouse, France; Gustave Roussy Cancer Campus, Villejuif, France; Institut de Cancérologie de l'Ouest, Nantes, France; Institut Curie, Paris, France; Unicancer, Paris, France; Centre Antoine Lacassagne, Nice, France; Centre Eugène Marquis, Rennes, France; Institut Bergonié, Bordeaux, France
| | - M-P Sablin
- Institut Paoli Calmettes, Marseille, France; Centre Léon Bérard, Lyon, France; Institut Claudius Regaud- IUCT-O, Toulouse, France; Gustave Roussy Cancer Campus, Villejuif, France; Institut de Cancérologie de l'Ouest, Nantes, France; Institut Curie, Paris, France; Unicancer, Paris, France; Centre Antoine Lacassagne, Nice, France; Centre Eugène Marquis, Rennes, France; Institut Bergonié, Bordeaux, France
| | - M Jimenez
- Institut Paoli Calmettes, Marseille, France; Centre Léon Bérard, Lyon, France; Institut Claudius Regaud- IUCT-O, Toulouse, France; Gustave Roussy Cancer Campus, Villejuif, France; Institut de Cancérologie de l'Ouest, Nantes, France; Institut Curie, Paris, France; Unicancer, Paris, France; Centre Antoine Lacassagne, Nice, France; Centre Eugène Marquis, Rennes, France; Institut Bergonié, Bordeaux, France
| | - J-M Ferrero
- Institut Paoli Calmettes, Marseille, France; Centre Léon Bérard, Lyon, France; Institut Claudius Regaud- IUCT-O, Toulouse, France; Gustave Roussy Cancer Campus, Villejuif, France; Institut de Cancérologie de l'Ouest, Nantes, France; Institut Curie, Paris, France; Unicancer, Paris, France; Centre Antoine Lacassagne, Nice, France; Centre Eugène Marquis, Rennes, France; Institut Bergonié, Bordeaux, France
| | - C Lefeuvre-Plesse
- Institut Paoli Calmettes, Marseille, France; Centre Léon Bérard, Lyon, France; Institut Claudius Regaud- IUCT-O, Toulouse, France; Gustave Roussy Cancer Campus, Villejuif, France; Institut de Cancérologie de l'Ouest, Nantes, France; Institut Curie, Paris, France; Unicancer, Paris, France; Centre Antoine Lacassagne, Nice, France; Centre Eugène Marquis, Rennes, France; Institut Bergonié, Bordeaux, France
| | - H Bonnefoi
- Institut Paoli Calmettes, Marseille, France; Centre Léon Bérard, Lyon, France; Institut Claudius Regaud- IUCT-O, Toulouse, France; Gustave Roussy Cancer Campus, Villejuif, France; Institut de Cancérologie de l'Ouest, Nantes, France; Institut Curie, Paris, France; Unicancer, Paris, France; Centre Antoine Lacassagne, Nice, France; Centre Eugène Marquis, Rennes, France; Institut Bergonié, Bordeaux, France
| | - V Attignon
- Institut Paoli Calmettes, Marseille, France; Centre Léon Bérard, Lyon, France; Institut Claudius Regaud- IUCT-O, Toulouse, France; Gustave Roussy Cancer Campus, Villejuif, France; Institut de Cancérologie de l'Ouest, Nantes, France; Institut Curie, Paris, France; Unicancer, Paris, France; Centre Antoine Lacassagne, Nice, France; Centre Eugène Marquis, Rennes, France; Institut Bergonié, Bordeaux, France
| | - I Soubeyran
- Institut Paoli Calmettes, Marseille, France; Centre Léon Bérard, Lyon, France; Institut Claudius Regaud- IUCT-O, Toulouse, France; Gustave Roussy Cancer Campus, Villejuif, France; Institut de Cancérologie de l'Ouest, Nantes, France; Institut Curie, Paris, France; Unicancer, Paris, France; Centre Antoine Lacassagne, Nice, France; Centre Eugène Marquis, Rennes, France; Institut Bergonié, Bordeaux, France
| | - P Jezequel
- Institut Paoli Calmettes, Marseille, France; Centre Léon Bérard, Lyon, France; Institut Claudius Regaud- IUCT-O, Toulouse, France; Gustave Roussy Cancer Campus, Villejuif, France; Institut de Cancérologie de l'Ouest, Nantes, France; Institut Curie, Paris, France; Unicancer, Paris, France; Centre Antoine Lacassagne, Nice, France; Centre Eugène Marquis, Rennes, France; Institut Bergonié, Bordeaux, France
| | - F Commo
- Institut Paoli Calmettes, Marseille, France; Centre Léon Bérard, Lyon, France; Institut Claudius Regaud- IUCT-O, Toulouse, France; Gustave Roussy Cancer Campus, Villejuif, France; Institut de Cancérologie de l'Ouest, Nantes, France; Institut Curie, Paris, France; Unicancer, Paris, France; Centre Antoine Lacassagne, Nice, France; Centre Eugène Marquis, Rennes, France; Institut Bergonié, Bordeaux, France
| | - F André
- Institut Paoli Calmettes, Marseille, France; Centre Léon Bérard, Lyon, France; Institut Claudius Regaud- IUCT-O, Toulouse, France; Gustave Roussy Cancer Campus, Villejuif, France; Institut de Cancérologie de l'Ouest, Nantes, France; Institut Curie, Paris, France; Unicancer, Paris, France; Centre Antoine Lacassagne, Nice, France; Centre Eugène Marquis, Rennes, France; Institut Bergonié, Bordeaux, France
| |
Collapse
|
16
|
Cottu PH, Boulai A, Callens C, Baulande S, Legoix-Ne P, Bernard V, Vincent-Salomon A, Benhamo V, Brain EGC, Chemlali W, Campone M, Bachelot TD, Giacchetti S, Bonneterre J, Bidard FC, Servois V, Comte A, Belin L, Sigal B, Bièche I. Abstract PD1-06: Comparison of mutational landscapes of primary breast cancer and first metastatic relapse: Results from the ESOPE study. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-pd1-06] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
Genomic profile of breast cancer metastases (M) may differ from that of the primary tumor (PT). In a multicenter prospective study (ESOPE, NCT 01956552) including 130 patients with biopsies of the first metastatic deposit, we have shown that luminal breast cancers are the most prone to phenotypical subtype changes (Comte et al, ASCO 2016#550). We report here the first results of a comparative PT/M targeted next generation sequencing (NGS) mutational analysis.
Methods
Of 130 patients, 117 paired PT/M samples obtained before any treatment were available for analysis. Targeted Sequencing was done using Illumina Hiseq2500 technology with a custom made 95 breast cancer associated genes panel. Sequence data were aligned to the human reference genome (hg19) using Bowtie2 algorithm. Median depth was 607X and 87% of targets achieved 100X depth. SNVs and indels were called using GATK UnifiedGenotyper. We retained COSMIC confirmed non synonymous, exonic/splice variants and observed at a frequency lower than 0,1% in population. Further confirmation of detected variants was performed with comparison to public databases (cbioportal, tumorportal), and potential pathogenicity was evaluated with 4 different public algorithms. We present here the results obtained from the first 35 matched PT/M samples (liver mets 68%), focusing analysis on 40 genes including PIK3CA (20 genes), ER (6 genes) and MAPK (11 genes) pathways, RUNX1, CDH1 and TP53 genes.
Results
Patients characteristics are representative of patients with first line metastatic breast cancer (Comte et al, ASCO 2016#550). Among the 40 genes analyzed in the 70 samples, we detected 134 somatic mutations (70 in PT and 64 in M) including 15 indels and 119 SNV. Among these 134 mutations there were 74 different mutations (66SNV and 8 indels) classified pathogenic for 26 and of unknown pathogenicity for 48 of them. We detected at least 1 mutation in 31 PT and in 28 M. Median numbers of mutations were 1 in PT (range 1-9) and 1 in M (range1-22) samples (p=0.295, Wilcoxon rank sum test). Top ten mutated genes in PT included PIK3CA, TP53, NCOR1, NF1, GATA3, CDH1, ERBB3, PTEN, HRAS, INPP4B. In M samples, the 10 top genes were PIK3CA, TP53, ERBB3, AKT3, CDH1, ERBB4, GATA3, INPP4B, MET, MTOR. Only 3 ESR1 mutations were detected, including 1 PT/M pair and 1 M. Beyond highly shared PIK3CA and TP53 mutations, overall crude PT/M discordance rate was 31%. Analysis by histological subtypes showed PT and M specific mutational profiles, suggesting a role in ERB gene family (notably ERBB3) and MAPK driven pathways in early metastatic progression. Specific metastatic site analysis suggested enrichment in MAPK pathway mutations in liver metastases when compared to other sites. Variant allelic fractions were globally not significantly different between PT and M samples.
Conclusion
In this prospective multicenter series of systematic biopsies of first metastases, we report a targeted mutational analysis of matched PT and M samples not modified by previous therapy exposure. Early analyses suggest specific genotypical changes according to tumor subtype and/or metastatic site. Extended and updated results will be reported at the meeting.
Citation Format: Cottu PH, Boulai A, Callens C, Baulande S, Legoix-Ne P, Bernard V, Vincent-Salomon A, Benhamo V, Brain EGC, Chemlali W, Campone M, Bachelot TD, Giacchetti S, Bonneterre J, Bidard F-C, Servois V, Comte A, Belin L, Sigal B, Bièche I. Comparison of mutational landscapes of primary breast cancer and first metastatic relapse: Results from the ESOPE study [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr PD1-06.
Collapse
Affiliation(s)
- PH Cottu
- Institut Curie, Paris, France; Institut Curie, Saint Cloud, France; Institut de Cancerologie de l'Ouest, Saint Herblain, France; Centre Leon Berard, Lyon, France; CHU Saint Louis, Paris, France; Centre Oscar Lambret, Lille, France
| | - A Boulai
- Institut Curie, Paris, France; Institut Curie, Saint Cloud, France; Institut de Cancerologie de l'Ouest, Saint Herblain, France; Centre Leon Berard, Lyon, France; CHU Saint Louis, Paris, France; Centre Oscar Lambret, Lille, France
| | - C Callens
- Institut Curie, Paris, France; Institut Curie, Saint Cloud, France; Institut de Cancerologie de l'Ouest, Saint Herblain, France; Centre Leon Berard, Lyon, France; CHU Saint Louis, Paris, France; Centre Oscar Lambret, Lille, France
| | - S Baulande
- Institut Curie, Paris, France; Institut Curie, Saint Cloud, France; Institut de Cancerologie de l'Ouest, Saint Herblain, France; Centre Leon Berard, Lyon, France; CHU Saint Louis, Paris, France; Centre Oscar Lambret, Lille, France
| | - P Legoix-Ne
- Institut Curie, Paris, France; Institut Curie, Saint Cloud, France; Institut de Cancerologie de l'Ouest, Saint Herblain, France; Centre Leon Berard, Lyon, France; CHU Saint Louis, Paris, France; Centre Oscar Lambret, Lille, France
| | - V Bernard
- Institut Curie, Paris, France; Institut Curie, Saint Cloud, France; Institut de Cancerologie de l'Ouest, Saint Herblain, France; Centre Leon Berard, Lyon, France; CHU Saint Louis, Paris, France; Centre Oscar Lambret, Lille, France
| | - A Vincent-Salomon
- Institut Curie, Paris, France; Institut Curie, Saint Cloud, France; Institut de Cancerologie de l'Ouest, Saint Herblain, France; Centre Leon Berard, Lyon, France; CHU Saint Louis, Paris, France; Centre Oscar Lambret, Lille, France
| | - V Benhamo
- Institut Curie, Paris, France; Institut Curie, Saint Cloud, France; Institut de Cancerologie de l'Ouest, Saint Herblain, France; Centre Leon Berard, Lyon, France; CHU Saint Louis, Paris, France; Centre Oscar Lambret, Lille, France
| | - EGC Brain
- Institut Curie, Paris, France; Institut Curie, Saint Cloud, France; Institut de Cancerologie de l'Ouest, Saint Herblain, France; Centre Leon Berard, Lyon, France; CHU Saint Louis, Paris, France; Centre Oscar Lambret, Lille, France
| | - W Chemlali
- Institut Curie, Paris, France; Institut Curie, Saint Cloud, France; Institut de Cancerologie de l'Ouest, Saint Herblain, France; Centre Leon Berard, Lyon, France; CHU Saint Louis, Paris, France; Centre Oscar Lambret, Lille, France
| | - M Campone
- Institut Curie, Paris, France; Institut Curie, Saint Cloud, France; Institut de Cancerologie de l'Ouest, Saint Herblain, France; Centre Leon Berard, Lyon, France; CHU Saint Louis, Paris, France; Centre Oscar Lambret, Lille, France
| | - TD Bachelot
- Institut Curie, Paris, France; Institut Curie, Saint Cloud, France; Institut de Cancerologie de l'Ouest, Saint Herblain, France; Centre Leon Berard, Lyon, France; CHU Saint Louis, Paris, France; Centre Oscar Lambret, Lille, France
| | - S Giacchetti
- Institut Curie, Paris, France; Institut Curie, Saint Cloud, France; Institut de Cancerologie de l'Ouest, Saint Herblain, France; Centre Leon Berard, Lyon, France; CHU Saint Louis, Paris, France; Centre Oscar Lambret, Lille, France
| | - J Bonneterre
- Institut Curie, Paris, France; Institut Curie, Saint Cloud, France; Institut de Cancerologie de l'Ouest, Saint Herblain, France; Centre Leon Berard, Lyon, France; CHU Saint Louis, Paris, France; Centre Oscar Lambret, Lille, France
| | - F-C Bidard
- Institut Curie, Paris, France; Institut Curie, Saint Cloud, France; Institut de Cancerologie de l'Ouest, Saint Herblain, France; Centre Leon Berard, Lyon, France; CHU Saint Louis, Paris, France; Centre Oscar Lambret, Lille, France
| | - V Servois
- Institut Curie, Paris, France; Institut Curie, Saint Cloud, France; Institut de Cancerologie de l'Ouest, Saint Herblain, France; Centre Leon Berard, Lyon, France; CHU Saint Louis, Paris, France; Centre Oscar Lambret, Lille, France
| | - A Comte
- Institut Curie, Paris, France; Institut Curie, Saint Cloud, France; Institut de Cancerologie de l'Ouest, Saint Herblain, France; Centre Leon Berard, Lyon, France; CHU Saint Louis, Paris, France; Centre Oscar Lambret, Lille, France
| | - L Belin
- Institut Curie, Paris, France; Institut Curie, Saint Cloud, France; Institut de Cancerologie de l'Ouest, Saint Herblain, France; Centre Leon Berard, Lyon, France; CHU Saint Louis, Paris, France; Centre Oscar Lambret, Lille, France
| | - B Sigal
- Institut Curie, Paris, France; Institut Curie, Saint Cloud, France; Institut de Cancerologie de l'Ouest, Saint Herblain, France; Centre Leon Berard, Lyon, France; CHU Saint Louis, Paris, France; Centre Oscar Lambret, Lille, France
| | - I Bièche
- Institut Curie, Paris, France; Institut Curie, Saint Cloud, France; Institut de Cancerologie de l'Ouest, Saint Herblain, France; Centre Leon Berard, Lyon, France; CHU Saint Louis, Paris, France; Centre Oscar Lambret, Lille, France
| |
Collapse
|
17
|
Tarcic G, Kamal M, Edelheit O, Barbash Z, Vidne M, Miron B, Callens C, Servant N, Bièche I, Le Tourneau C. Functional mutational analysis to assess the oncogenic activity of variant of uncertain significance (VUS) detected in patients included in the SHIVA trial. Eur J Cancer 2016. [DOI: 10.1016/s0959-8049(16)32618-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
18
|
De Plater L, Deas O, Guibaudet C, Nicolas A, Couturier J, Zemoura L, Bièche I, Ouafi L, Chapelier A, Livartowski A, De Cremoux P, Daniel C, Roman-Roman S, Judde J, Decaudin D. Assessment of Pi3K and/or MAPK signaling pathway targeting in KRAS- or PIK3CA-mutated and wild type non-small cell lung cancer patient-derived xenografts. Eur J Cancer 2016. [DOI: 10.1016/s0959-8049(16)32987-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
19
|
De Plater L, Deas O, Guibaudet C, Nicolas A, Couturier J, Zemoura L, Bièche I, Ouafi L, Chapelier A, Livartowski A, De Cremoux P, Daniel C, Roman-Roman S, Judde J, Decaudin D. Assessment of EGFR-dependent signaling pathway targeting in EGFR-mutated and wild type non-small cell lung cancer patient-derived xenografts. Eur J Cancer 2016. [DOI: 10.1016/s0959-8049(16)32986-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
20
|
Le goux C, Damotte D, Vacher S, Barry-delongchamps N, Sibony M, Terris B, Zerbib M, Bièche I, Pignot G. Valeur pronostique de PLEKHS1 dans la carcinogénèse urothéliale vésicale. Prog Urol 2016. [DOI: 10.1016/j.purol.2016.07.197] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
21
|
Comte A, Sigal-Zafrani B, Belin L, Bièche I, Callens C, Diéras V, Bidard FC, Mariani O, Servois V, Szwarc D, Vincent-Salomon A, Brain ECG, Cottu PH. Abstract P2-05-06: Clinical utility of systematic biopsy of first metastatic event in breast cancer: Results from a prospective multicenter trial. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p2-05-06] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
BACKGROUND: Cumulative evidence for phenotypic and molecular heterogeneity between primary breast cancer (BC) site and matched metastasis (mets) has been obtained in retrospective studies. Current expert consensus suggests performing biopsies of mets, but clinical utility and cost are unknown. The primary objective of the ESOPE study (NCT01956552) was to compare the phenotype and genotype of the primary tumor (PT) with those of matched mets at time of first distant relapse, before the start of any treatment, in order to optimize the treatment of mets
PATIENTS and METHODS: Between Nov. 2010 and Sept. 2013, we conducted a prospective multicenter study on BC patients (pts) with diagnosis of first mets. All pts were to have available Formalin-Fixed Paraffin-Embedded (FFPE) PT sample and mets accessible to either percutaneous or surgical sampling. All tissue samples were centrally analyzed with immunohistochemistry (ER, PgR, HER2, and Ki67) and FISH when indicated. Frozen samples were stored for further analyses. We recorded intended therapeutic decision before and after biopsy.
RESULTS: Of 93 pts included, 89 were eligible for biopsy. Median age was 57 years (28-81); median interval between PT and mets was 42 months (0-211), including 14 pts with novo metastatic breast cancer. Mets biopsy was performed in 85 pts (96%, refusal n=2, not feasible n=2). Toxicity was limited to only 1 grade 1 hemorrhage. Sampled sites were liver (44%), lung (16%), bone (13%), lymph node (13%), skin/muscle/chest wall (9%), ovary/peritoneum (4%), and adrenal gland (1%). PT was not available in 4 pts; mets biopsy was non contributive in 6 pts but led to a diagnosis of second primary cancer in 3 pts.
In 72 pts with matched PT and mets, PT were luminal A (n=11), luminal B (n=33), triple negative (n=13), HER2 (n=13), non-evaluable (n=2). Mets were luminal A (n=6), luminal B (n=30), triple negative (n=16), HER2 (n=14), non-evaluable (n=6). Discrepancy rates were: ER 18% [kappa for concordance =0.6, CI 95 % (0.42-0.77)], PgR: 39% [kappa=0.19, CI 95% (0.01-0.39)], Her2: 4% [kappa=0.86, CI 95% (0.7-1)], Ki67: 25% [kappa=0.19, CI 95% (-0.09; 0.49)].
The most frequent discrepancy rate was observed in pts with lum A PT, as only 3/10 developed Lum A mets. HER2 and triple negative were the most stable subtypes (12/13 and 12/12 respectively). Most importantly, mets biopsy led to a change in therapeutic decision in 25 pts (independent evaluation by 2 oncologists). Additional comparative targeted NGS analyses are ongoing on a first subset of 54 FFPE paired samples, and parallel whole exome sequencing is planned on 38 paired samples with available constitutional DNA.
CONCLUSION: Comparative analysis of breast cancer PT and first mets is routinely feasible, with very low morbidity and a significant impact for patients' management: 29% had a second cancer diagnosis or were proposed a therapeutic change. Furthermore, this study will provide additional data on quality and quantity of tissue available for molecular analysis, and ultimately in terms of cost-efficacy.
Citation Format: Comte A, Sigal-Zafrani B, Belin L, Bièche I, Callens C, Diéras V, Bidard F-C, Mariani O, Servois V, Szwarc D, Vincent-Salomon A, Brain ECG, Cottu PH. Clinical utility of systematic biopsy of first metastatic event in breast cancer: Results from a prospective multicenter trial. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P2-05-06.
Collapse
Affiliation(s)
- A Comte
- Institut Curie, Paris, France; Institut Curie, Saint Cloud, France
| | - B Sigal-Zafrani
- Institut Curie, Paris, France; Institut Curie, Saint Cloud, France
| | - L Belin
- Institut Curie, Paris, France; Institut Curie, Saint Cloud, France
| | - I Bièche
- Institut Curie, Paris, France; Institut Curie, Saint Cloud, France
| | - C Callens
- Institut Curie, Paris, France; Institut Curie, Saint Cloud, France
| | - V Diéras
- Institut Curie, Paris, France; Institut Curie, Saint Cloud, France
| | - F-C Bidard
- Institut Curie, Paris, France; Institut Curie, Saint Cloud, France
| | - O Mariani
- Institut Curie, Paris, France; Institut Curie, Saint Cloud, France
| | - V Servois
- Institut Curie, Paris, France; Institut Curie, Saint Cloud, France
| | - D Szwarc
- Institut Curie, Paris, France; Institut Curie, Saint Cloud, France
| | | | - ECG Brain
- Institut Curie, Paris, France; Institut Curie, Saint Cloud, France
| | - PH Cottu
- Institut Curie, Paris, France; Institut Curie, Saint Cloud, France
| |
Collapse
|
22
|
Tury S, Becette V, Assayag F, Vacher S, Marangoni E, Bièche I, Lerebours F, Callens C. Abstract P4-09-03: Prognostic and predictive value of COX2 in breast cancer, correlation with PIK3CA mutations. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p4-09-03] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Cyclooxygenase-2 (COX2) is responsible for the synthesis of prostaglandins from arachidonic acid. This enzyme is weakly expressed in normal tissues and implicated in oncogenic and inflammatory processes. Treatment with a COX2 inhibitor (aspirin) increases overall survival of patients with colorectal cancer only for PIK3CA mutated tumors confirming an interaction between COX2 and the PI3K/AKT pathway. PIK3CA gene mutations are detected in 10-40% of BC depending on the molecular subtype. We hypothesized that COX inhibition could have an impact in Breast Cancer (BC) treatment.
Methods: COX2 mRNA expression levels were analyzed in 446 BC samples and 61 patient-derived xenografts (PDX) using qRT-PCR. Protein expression of COX2 was studied by immunohistochemistry (IHC) in 26 BC and 14 PDX. The prognostic impact of COX2 expression level according to PIK3CA mutation status was also analyzed in BC patients. The activity of celecoxib, a selective COX2 inhibitor, was tested in two PDX of triple-negative BC: the HBCx50 PDX (PIK3CA wild-type, expressing COX2) and the HBCx4B PDX (PIK3CA mutated, expressing COX2).
Results: COX2 transcript was under-expressed in 74% and overexpressed in 2% of the BC samples. COX2 overexpression is significantly associated with triple-negative subtype (11%, 7/68 cases, p<0.0001). Moreover, immunostaining of COX2 was well correlated with COX2 mRNA expression level. PIK3CA mutations were detected in 33% of patients. We showed that metastasis-free survival (MFS) was significantly better in patients who do not under-express COX2 (p=0.007) or in patients with PIK3CA mutation (p=0.02) regardless the BC subtype and adjuvant treatment. In the PIK3CA wild-type (wt) subgroup, MFS of patients was significantly better in patients not under-expressing COX2 than in patients under-expressing COX2 (p=0.01). In PDX, the strongest expression levels of COX2 were found in triple-negative (median 36 [0-1673]) compared to luminal (median 0 [0-202]) and HER2 positive subtypes (median 6 [0-601]). In vivo studies showed that celecoxib has no effect on the HBCx50 (PIK3CA wt) PDX growth while a significant antitumoral effect of celecoxib is observed in HBCx4B (PIK3CA mutated) PDX (tumor growth inhibition=41%, p=0.03).
Conclusion: In BC, COX2 underexpression is frequent and impact prognosis. BC overexpressing COX2 are rare and mainly belong to the triple-negative subtype. In vivo PDX studies show that the antitumoral effect of celecoxib may be restricted to BC expressing COX2 with PIK3CA mutation. Analyses of signaling pathways, expression levels of COX2 and its target proteins, tumor proliferation and apoptosis induction are ongoing on tumors and serum of mice to elucidate the antitumoral effect of celecoxib. This work could help to identify a subgroup of BC patients who may benefit from celecoxib especially as COX2 immunostaining and PIK3CA mutation status could routinely be used as COX2 inhibitor sensitivity biomarkers. These results need to be validated in a phase II clinical trial.
Citation Format: Tury S, Becette V, Assayag F, Vacher S, Marangoni E, Bièche I, Lerebours F, Callens C. Prognostic and predictive value of COX2 in breast cancer, correlation with PIK3CA mutations. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P4-09-03.
Collapse
Affiliation(s)
- S Tury
- Instiut Curie, Paris, France; Institut Curie, Hôpital René Huguenin, Saint Cloud, France
| | - V Becette
- Instiut Curie, Paris, France; Institut Curie, Hôpital René Huguenin, Saint Cloud, France
| | - F Assayag
- Instiut Curie, Paris, France; Institut Curie, Hôpital René Huguenin, Saint Cloud, France
| | - S Vacher
- Instiut Curie, Paris, France; Institut Curie, Hôpital René Huguenin, Saint Cloud, France
| | - E Marangoni
- Instiut Curie, Paris, France; Institut Curie, Hôpital René Huguenin, Saint Cloud, France
| | - I Bièche
- Instiut Curie, Paris, France; Institut Curie, Hôpital René Huguenin, Saint Cloud, France
| | - F Lerebours
- Instiut Curie, Paris, France; Institut Curie, Hôpital René Huguenin, Saint Cloud, France
| | - C Callens
- Instiut Curie, Paris, France; Institut Curie, Hôpital René Huguenin, Saint Cloud, France
| |
Collapse
|
23
|
Marous M, Bièche I, Paoletti X, Alt M, Razak A, Stathis A, Kamal M, Le Tourneau C. Designs of preoperative biomarkers trials in oncology: a systematic review of the literature. Ann Oncol 2015; 26:2419-28. [DOI: 10.1093/annonc/mdv378] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2015] [Accepted: 08/19/2015] [Indexed: 01/06/2023] Open
|
24
|
Lodillinsky C, Infante E, Guichard A, Chaligné R, Fuhrmann L, Cyrta J, Irondelle M, Lagoutte E, Vacher S, Bonsang-Kitzis H, Glukhova M, Reyal F, Bièche I, Vincent-Salomon A, Chavrier P. p63/MT1-MMP axis is required for in situ to invasive transition in basal-like breast cancer. Oncogene 2015; 35:344-57. [PMID: 25893299 DOI: 10.1038/onc.2015.87] [Citation(s) in RCA: 65] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/18/2014] [Revised: 01/29/2015] [Accepted: 02/22/2015] [Indexed: 01/01/2023]
Abstract
The transition of ductal carcinoma in situ (DCIS) to invasive breast carcinoma requires tumor cells to cross the basement membrane (BM). However, mechanisms underlying BM transmigration are poorly understood. Here, we report that expression of membrane-type 1 (MT1)-matrix metalloproteinase (MMP), a key component of the BM invasion program, increases during breast cancer progression at the in situ to invasive breast carcinoma transition. In the intraductal xenograft model, MT1-MMP is required for BM transmigration of MCF10DCIS.com breast adenocarcinoma cells and is overexpressed in cell clusters overlying focal BM disruptions and at the invasive tumor front. Mirrored upregulation of p63 and MT1-MMP is observed at the edge of MCF10DCIS.com xenograft tumors and p63 is required for induction of MT1-MMP-dependent invasive program in response to microenvironmental signals. Immunohistochemistry and analysis of public database reveal that p63 and MT1-MMP are upregulated in human basal-like breast tumors suggesting that p63/MT1-MMP axis contributes to progression of basal-like breast cancers with elevated p63 and MT1-MMP levels.
Collapse
Affiliation(s)
- C Lodillinsky
- Membrane and Cytoskeleton Dynamics Group, Cell Dynamics and Compartmentalization Unit, Institut Curie, Centre National de la Recherche Scientifique UMR144, Paris, France
| | - E Infante
- Membrane and Cytoskeleton Dynamics Group, Cell Dynamics and Compartmentalization Unit, Institut Curie, Centre National de la Recherche Scientifique UMR144, Paris, France
| | - A Guichard
- Membrane and Cytoskeleton Dynamics Group, Cell Dynamics and Compartmentalization Unit, Institut Curie, Centre National de la Recherche Scientifique UMR144, Paris, France
| | - R Chaligné
- Mammalian Developmental Epigenetics Group, Genetics and Developmental Biology Unit, Institut Curie, Paris, France
| | - L Fuhrmann
- Membrane and Cytoskeleton Dynamics Group, Cell Dynamics and Compartmentalization Unit, Institut Curie, Centre National de la Recherche Scientifique UMR144, Paris, France
| | - J Cyrta
- Membrane and Cytoskeleton Dynamics Group, Cell Dynamics and Compartmentalization Unit, Institut Curie, Centre National de la Recherche Scientifique UMR144, Paris, France
| | - M Irondelle
- Membrane and Cytoskeleton Dynamics Group, Cell Dynamics and Compartmentalization Unit, Institut Curie, Centre National de la Recherche Scientifique UMR144, Paris, France
| | - E Lagoutte
- Membrane and Cytoskeleton Dynamics Group, Cell Dynamics and Compartmentalization Unit, Institut Curie, Centre National de la Recherche Scientifique UMR144, Paris, France
| | - S Vacher
- Department of Genetics, Institut Curie, Paris, France
| | - H Bonsang-Kitzis
- RT2Lab Team, Translational Research Department, Institut Curie, Paris, France
| | - M Glukhova
- Molecular Mechanisms of Mammary Gland Development Group, Cell Dynamics and Compartmentalization Unit, Institut Curie, Centre National de la Recherche Scientifique UMR144, Paris, France
| | - F Reyal
- RT2Lab Team, Translational Research Department, Institut Curie, Paris, France
| | - I Bièche
- Department of Genetics, Institut Curie, Paris, France
| | - A Vincent-Salomon
- Mammalian Developmental Epigenetics Group, Genetics and Developmental Biology Unit, Institut Curie, Paris, France.,Pathology Department, Institut Curie, Paris, France
| | - P Chavrier
- Membrane and Cytoskeleton Dynamics Group, Cell Dynamics and Compartmentalization Unit, Institut Curie, Centre National de la Recherche Scientifique UMR144, Paris, France
| |
Collapse
|
25
|
Rondeau S, Vacher S, De Koning L, Briaux A, Schnitzler A, Chemlali W, Callens C, Lidereau R, Bièche I. ATM has a major role in the double-strand break repair pathway dysregulation in sporadic breast carcinomas and is an independent prognostic marker at both mRNA and protein levels. Br J Cancer 2015; 112:1059-66. [PMID: 25742469 PMCID: PMC4366900 DOI: 10.1038/bjc.2015.60] [Citation(s) in RCA: 37] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2014] [Revised: 01/08/2015] [Accepted: 01/12/2015] [Indexed: 12/19/2022] Open
Abstract
BACKGROUND Ataxia telangiectasia mutated (ATM) is a kinase that has a central role in the maintenance of genomic integrity by activating cell cycle checkpoints and promoting repair of DNA double-strand breaks (DSB). In breast cancer, a low level of ATM was correlated with poor outcome; however, the molecular mechanism of this downregulation is still unclear. METHODS We used qRT-PCR assay to quantify mRNA levels of ATM gene in 454 breast tumours from patients with known clinical/pathological status and outcome; reverse phase protein arrays (RPPA) were used to assess the levels of ATM and 14 proteins in 233 breast tumours. RESULTS ATM mRNA was associated with poor metastasis-free survival (MFS) (P=0.00012) on univariate analysis. ATM mRNA and protein levels were positively correlated (P=0.00040). A low level of ATM protein was correlated with poorer MFS (P=0.000025). ATM expression at mRNA or protein levels are independent prognostic factors on multivariate analysis (P=0.00046 and P=0.00037, respectively). The ATM protein level was positively correlated with the levels of six proteins of the DSB repair pathway: H2AX (P<0.0000001), XRCC5 (P<0.0000001), NBN (P<0.0000001), Mre11 (P=0.0000029), Rad50 (P=0.0064), and TP53BP1 (P=0.026), but not with proteins involved in other pathways that are altered in cancer. Low expression of ATM protein was significantly associated with high miR-203 expression (P=0.011). CONCLUSION We confirmed that ATM expression is an independent prognostic marker at both RNA and protein levels. We showed that alteration of ATM is involved in dysregulation of the DSB repair pathway. Finally, miR-203 may be responsible for downregulation of ATM in breast cancers.
Collapse
Affiliation(s)
- S Rondeau
- Pharmacogenomics Unit, Department of Genetics, Institut Curie, 26 rue d'Ulm, Paris 75005, France
| | - S Vacher
- Pharmacogenomics Unit, Department of Genetics, Institut Curie, 26 rue d'Ulm, Paris 75005, France
| | - L De Koning
- Department of Translational Research, Institut Curie, 26 rue d'Ulm, Paris 75005, France
| | - A Briaux
- Pharmacogenomics Unit, Department of Genetics, Institut Curie, 26 rue d'Ulm, Paris 75005, France
| | - A Schnitzler
- Pharmacogenomics Unit, Department of Genetics, Institut Curie, 26 rue d'Ulm, Paris 75005, France
| | - W Chemlali
- Pharmacogenomics Unit, Department of Genetics, Institut Curie, 26 rue d'Ulm, Paris 75005, France
| | - C Callens
- Pharmacogenomics Unit, Department of Genetics, Institut Curie, 26 rue d'Ulm, Paris 75005, France
| | - R Lidereau
- Pharmacogenomics Unit, Department of Genetics, Institut Curie, 26 rue d'Ulm, Paris 75005, France
| | - I Bièche
- 1] Pharmacogenomics Unit, Department of Genetics, Institut Curie, 26 rue d'Ulm, Paris 75005, France [2] EA7331, University of Paris Descartes, 4 Avenue de l'Observatoire, Paris 75006, France
| |
Collapse
|
26
|
Beau-Faller M, Texier M, Blons H, Richard N, Escande F, Bièche I, Lizard S, De Fraipont F, Morin F, Zalcman G, Pignon J, Cadranel J. Ermetic-2 Project : Impact of Systematic Egfr and Kras Mutation Evaluation By Alternative Testing Methods on Progression-Free (Pfs) and Overall Survival (Os) in Patients with Advanced Non–Small-Cell Lung Cancer (Nsclc) Treated By Erlotinib (E) in the Ifct Ermetic Cohort. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu349.88] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
27
|
Le Tourneau C, Paoletti X, Servant N, Bièche I, Gentien D, Rio Frio T, Vincent-Salomon A, Servois V, Romejon J, Mariani O, Bernard V, Huppe P, Pierron G, Mulot F, Callens C, Wong J, Mauborgne C, Rouleau E, Reyes C, Henry E, Leroy Q, Gestraud P, La Rosa P, Escalup L, Mitry E, Trédan O, Delord JP, Campone M, Goncalves A, Isambert N, Gavoille C, Kamal M. Randomised proof-of-concept phase II trial comparing targeted therapy based on tumour molecular profiling vs conventional therapy in patients with refractory cancer: results of the feasibility part of the SHIVA trial. Br J Cancer 2014; 111:17-24. [PMID: 24762958 PMCID: PMC4090722 DOI: 10.1038/bjc.2014.211] [Citation(s) in RCA: 55] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2014] [Revised: 03/24/2014] [Accepted: 03/27/2014] [Indexed: 12/24/2022] Open
Abstract
Background: The SHIVA trial is a multicentric randomised proof-of-concept phase II trial comparing molecularly targeted therapy based on tumour molecular profiling vs conventional therapy in patients with any type of refractory cancer. Results of the feasibility study on the first 100 enrolled patients are presented. Methods: Adult patients with any type of metastatic cancer who failed standard therapy were eligible for the study. The molecular profile was performed on a mandatory biopsy, and included mutations and gene copy number alteration analyses using high-throughput technologies, as well as the determination of oestrogen, progesterone, and androgen receptors by immunohistochemistry (IHC). Results: Biopsy was safely performed in 95 of the first 100 included patients. Median time between the biopsy and the therapeutic decision taken during a weekly molecular biology board was 26 days. Mutations, gene copy number alterations, and IHC analyses were successful in 63 (66%), 65 (68%), and 87 (92%) patients, respectively. A druggable molecular abnormality was present in 38 patients (40%). Conclusions: The establishment of a comprehensive tumour molecular profile was safe, feasible, and compatible with clinical practice in refractory cancer patients.
Collapse
Affiliation(s)
- C Le Tourneau
- 1] Institut Curie, Paris, France [2] Unité INSERM/Institut Curie U900, Paris, France [3] Institut Curie, Saint-Cloud, France
| | - X Paoletti
- 1] Institut Curie, Paris, France [2] Unité INSERM/Institut Curie U900, Paris, France
| | - N Servant
- 1] Institut Curie, Paris, France [2] Unité INSERM/Institut Curie U900, Paris, France
| | | | | | | | | | | | - J Romejon
- 1] Institut Curie, Paris, France [2] Unité INSERM/Institut Curie U900, Paris, France
| | | | | | - P Huppe
- 1] Institut Curie, Paris, France [2] Unité INSERM/Institut Curie U900, Paris, France
| | | | - F Mulot
- Institut Curie, Paris, France
| | | | - J Wong
- Institut Curie, Paris, France
| | | | | | - C Reyes
- Institut Curie, Paris, France
| | - E Henry
- Institut Curie, Paris, France
| | - Q Leroy
- Institut Curie, Paris, France
| | - P Gestraud
- 1] Institut Curie, Paris, France [2] Unité INSERM/Institut Curie U900, Paris, France
| | - P La Rosa
- 1] Institut Curie, Paris, France [2] Unité INSERM/Institut Curie U900, Paris, France
| | | | - E Mitry
- Institut Curie, Saint-Cloud, France
| | - O Trédan
- Centre Léon Bérard, Lyon, France
| | - J-P Delord
- Institut Claudius Régaud, Toulouse, France
| | - M Campone
- Centre René Gauducheau, Nantes, France
| | | | - N Isambert
- Centre Georges-François Leclerc, Dijon, France
| | | | - M Kamal
- Institut Curie, Paris, France
| |
Collapse
|
28
|
Cottu PH, Bièche I, de la Grange P, Gentien D, Assayag F, Thuleau A, El-Botty R, Chateau-Joubert S, Huerre M, Hatem R, Richon S, Slimane K, Marangoni E. Abstract P5-09-07: Identification of resistance-specific gene expression signatures in a breast cancer patient-derived xenograft with acquired resistance to different endocrine therapies. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p5-09-07] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background:
Acquired resistance to endocrine treatments (ET) occurs in more than 70% of cases of luminal breast cancer (LBC). We used patient derived xenografts (PDX) models of LBC to study molecular changes associated with acquired resistance to different ET modalities.
Methods:
A PDX model of LBC, established from an early stage BRCA2-mutated breast cancer, was treated with different ET (tamoxifen, fulvestrant, oophorectomy and letrozole) during several months. Tumors escaping to therapies were re-engrafted and maintained under therapy. ET-resistant and parental hormono-responders tumors were analyzed with immunohistochemistry (IHC), RT-PCR and Affymetrix Gene Expression Arrays. Hormono-resistant tumors were additionally studied for their in vivo response to ET, mTOR and PARP inhibitors.
Results:
From the initially ET sensitive HBCx22 xenograft model (Cottu, BCRT 2012) two resistant models were obtained respectively to tamoxifen (HBCx22-TamR) and to estrogen deprivation (HBCx22-OvaR). Unsupervised clustering of gene expression showed a clear cut separation between parental, TamR and OvaR tumors. Genes differentially expressed in TamR and OvaR tumors compared to parental HBCx22 were only partially overlapping. Up-Regulated genes in both TamR and OvaR tumors (n = 302) were involved in response to wounding, nucleotide metabolism, immune system, adhesion and cell growth. Biological Processes (BP) specifically deregulated in OvaR tumors (n = 380) included embryonic development, antigen presentation, amino acid and lipid metabolism. The top BP specifically regulated in TamR tumors (n = 1059) were response to estrogen and steroid hormones, TGF-b signaling, hypoxia, regulation of cell proliferation, with several strongly up-regulated genes of the histone clusters 1 and 3. Ingenuity Transcription Factor Analysis predicted activation of NFKB, SP1, AP-1 and JUN, and inhibition of ESR1. RT-PCR and IHC analyses confirmed the down regulation of ER controlled genes in the TamR tumors. Expression of ER co-regulators determined by RT-PCR showed that GREB1 was strongly reduced in TamR, while PBX1, GATA3 and FOXA1 were inhibited in OvaR. IHC analysis showed a loss of PTEN expression in HBCx22, with high levels of p-AKT and p-RPS6 in both parental and TamR and OvaR tumors. In vivo ET showed that the TamR xenograft was resistant to all modalities of ET, while OvaR was resistant to estrogen deprivation while retaining some sensitivity to tamoxifen and fulvestrant. Treatment with the mTOR inhibitor RAD001 arrested tumor growth but did not show any additive effect when combined to ET in TamR or OvaR tumors. Conversely, the combination of RAD001 with Olaparib was highly synergistic and induced complete tumor response in 70% of mice.
Conclusions:
According to the therapeutic selection, tumors derived from a PDX model of ER+ breast cancer show specific resistance patterns and gene expression profiles including disruption in the ER transcriptional program. The analysis of additional resistant tumors established from a second ER+ PDX will be presented at the meeting.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P5-09-07.
Collapse
Affiliation(s)
- PH Cottu
- Institut Curie, Paris, France; Genosplice, Evry, France; Ecole Vétérinaire d'Alfort, Maisons Alfort, France; Faculté de Pharmacie - Paris Descartes, Paris, France; Novartis, Rueil Malmaison, France
| | - I Bièche
- Institut Curie, Paris, France; Genosplice, Evry, France; Ecole Vétérinaire d'Alfort, Maisons Alfort, France; Faculté de Pharmacie - Paris Descartes, Paris, France; Novartis, Rueil Malmaison, France
| | - P de la Grange
- Institut Curie, Paris, France; Genosplice, Evry, France; Ecole Vétérinaire d'Alfort, Maisons Alfort, France; Faculté de Pharmacie - Paris Descartes, Paris, France; Novartis, Rueil Malmaison, France
| | - D Gentien
- Institut Curie, Paris, France; Genosplice, Evry, France; Ecole Vétérinaire d'Alfort, Maisons Alfort, France; Faculté de Pharmacie - Paris Descartes, Paris, France; Novartis, Rueil Malmaison, France
| | - F Assayag
- Institut Curie, Paris, France; Genosplice, Evry, France; Ecole Vétérinaire d'Alfort, Maisons Alfort, France; Faculté de Pharmacie - Paris Descartes, Paris, France; Novartis, Rueil Malmaison, France
| | - A Thuleau
- Institut Curie, Paris, France; Genosplice, Evry, France; Ecole Vétérinaire d'Alfort, Maisons Alfort, France; Faculté de Pharmacie - Paris Descartes, Paris, France; Novartis, Rueil Malmaison, France
| | - R El-Botty
- Institut Curie, Paris, France; Genosplice, Evry, France; Ecole Vétérinaire d'Alfort, Maisons Alfort, France; Faculté de Pharmacie - Paris Descartes, Paris, France; Novartis, Rueil Malmaison, France
| | - S Chateau-Joubert
- Institut Curie, Paris, France; Genosplice, Evry, France; Ecole Vétérinaire d'Alfort, Maisons Alfort, France; Faculté de Pharmacie - Paris Descartes, Paris, France; Novartis, Rueil Malmaison, France
| | - M Huerre
- Institut Curie, Paris, France; Genosplice, Evry, France; Ecole Vétérinaire d'Alfort, Maisons Alfort, France; Faculté de Pharmacie - Paris Descartes, Paris, France; Novartis, Rueil Malmaison, France
| | - R Hatem
- Institut Curie, Paris, France; Genosplice, Evry, France; Ecole Vétérinaire d'Alfort, Maisons Alfort, France; Faculté de Pharmacie - Paris Descartes, Paris, France; Novartis, Rueil Malmaison, France
| | - S Richon
- Institut Curie, Paris, France; Genosplice, Evry, France; Ecole Vétérinaire d'Alfort, Maisons Alfort, France; Faculté de Pharmacie - Paris Descartes, Paris, France; Novartis, Rueil Malmaison, France
| | - K Slimane
- Institut Curie, Paris, France; Genosplice, Evry, France; Ecole Vétérinaire d'Alfort, Maisons Alfort, France; Faculté de Pharmacie - Paris Descartes, Paris, France; Novartis, Rueil Malmaison, France
| | - E Marangoni
- Institut Curie, Paris, France; Genosplice, Evry, France; Ecole Vétérinaire d'Alfort, Maisons Alfort, France; Faculté de Pharmacie - Paris Descartes, Paris, France; Novartis, Rueil Malmaison, France
| |
Collapse
|
29
|
Beau-Faller M, Prim N, Ruppert AM, Nanni-Metéllus I, Lacave R, Lacroix L, Escande F, Lizard S, Pretet JL, Rouquette I, de Crémoux P, Solassol J, de Fraipont F, Bièche I, Cayre A, Favre-Guillevin E, Tomasini P, Wislez M, Besse B, Legrain M, Voegeli AC, Baudrin L, Morin F, Zalcman G, Quoix E, Blons H, Cadranel J. Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network. Ann Oncol 2013; 25:126-31. [PMID: 24285021 DOI: 10.1093/annonc/mdt418] [Citation(s) in RCA: 231] [Impact Index Per Article: 21.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open
Abstract
BACKGROUND There is scarce data available about epidermal growth factor receptor (EGFR) mutations other than common exon 19 deletions and exon 21 (L858R) mutations. PATIENTS AND METHODS EGFR exon 18 and/or exon 20 mutations were collected from 10 117 non-small-cell lung cancer (NSCLC) samples analysed at 15 French National Cancer Institute (INCa)-platforms of the ERMETIC-IFCT network. RESULTS Between 2008 and 2011, 1047 (10%) samples were EGFR-mutated, 102 (10%) with rare mutations: 41 (4%) in exon 18, 49 (5%) in exon 20, and 12 (1%) with other EGFR mutations. Exon 20 mutations were related to never-smoker status, when compared with exon 18 mutations (P < 0.001). Median overall survival (OS) of metastatic disease was 21 months [95% confidence interval (CI) 12-24], worse in smokers than in non-smoker patients with exon 20 mutations (12 versus 21 months; hazard ratio [HR] for death 0.27, 95% CI 0.08-0.87, P = 0.03). Under EGFR-tyrosine kinase inhibitors (TKIs), median OS was 14 months (95% CI 6-21); disease control rate was better for complex mutations (6 of 7, 86%) than for single mutations (16 of 40, 40%) (P = 0.03). CONCLUSIONS Rare EGFR-mutated NSCLCs are heterogeneous, with resistance of distal exon 20 insertions and better sensitivity of exon 18 or complex mutations to EGFR-TKIs, probably requiring individual assessment.
Collapse
Affiliation(s)
- M Beau-Faller
- Department of Biochemistry and Molecular Biology, Strasbourg University Hospital, Strasbourg
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Nunes M, Weiswald L, Vrignaud P, Vacher S, Turlotte E, Richon S, Roman-Roman S, Bièche I, Dangles-Marie V. Similar PI3K and RTK-RAS Status in Patient Derived Colorectal Cancer-Xenografts and Patients. Ann Oncol 2013. [DOI: 10.1093/annonc/mdt047.7] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
31
|
Meseure D, Drak elsibai K, Trassard M, Vacher S, le Ray C, Guinebretière JM, Lidereau R, Bièche I. MDGI, MIG-6 et EIG121 sont des inhibiteurs de la voie EGFR et des biomarqueurs potentiels de thérapies ciblées anti-EGFR dans les carcinomes mammaires invasifs. Ann Pathol 2012. [DOI: 10.1016/j.annpat.2012.09.220] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
32
|
Meseure D, Vacher S, Trassard M, Drak Alsibai K, Le Ray C, Régnier C, Lerebours F, Le Scodan R, Lidereau R, Bièche I. Rôles du complexe répresseur Polycomb EZH2/CBX7 et du long ARN non codant ANRIL dans l’induction des mécanismes de silencing épigénétique. Implications thérapeutiques potentielles dans les carcinomes mammaires de type triple négatif. Ann Pathol 2011. [DOI: 10.1016/j.annpat.2011.09.021] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
33
|
Guedj M, Marisa L, de Reynies A, Orsetti B, Schiappa R, Bibeau F, MacGrogan G, Lerebours F, Finetti P, Longy M, Bertheau P, Bertrand F, Bonnet F, Martin AL, Feugeas JP, Bièche I, Lehmann-Che J, Lidereau R, Birnbaum D, Bertucci F, de Thé H, Theillet C. A refined molecular taxonomy of breast cancer. Oncogene 2011; 31:1196-206. [PMID: 21785460 PMCID: PMC3307061 DOI: 10.1038/onc.2011.301] [Citation(s) in RCA: 190] [Impact Index Per Article: 14.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
The current histoclinical breast cancer classification is simple but imprecise. Several molecular classifications of breast cancers based on expression profiling have been proposed as alternatives. However, their reliability and clinical utility have been repeatedly questioned, notably because most of them were derived from relatively small initial patient populations. We analyzed the transcriptomes of 537 breast tumors using three unsupervised classification methods. A core subset of 355 tumors was assigned to six clusters by all three methods. These six subgroups overlapped with previously defined molecular classes of breast cancer, but also showed important differences, notably the absence of an ERBB2 subgroup and the division of the large luminal ER+ group into four subgroups, two of them being highly proliferative. Of the six subgroups, four were ER+/PR+/AR+, one was ER−/PR−/AR+ and one was triple negative (AR−/ER−/PR−). ERBB2-amplified tumors were split between the ER−/PR−/AR+ subgroup and the highly proliferative ER+ LumC subgroup. Importantly, each of these six molecular subgroups showed specific copy-number alterations. Gene expression changes were correlated to specific signaling pathways. Each of these six subgroups showed very significant differences in tumor grade, metastatic sites, relapse-free survival or response to chemotherapy. All these findings were validated on large external datasets including more than 3000 tumors. Our data thus indicate that these six molecular subgroups represent well-defined clinico-biological entities of breast cancer. Their identification should facilitate the detection of novel prognostic factors or therapeutical targets in breast cancer.
Collapse
Affiliation(s)
- M Guedj
- Ligue Nationale Contre le Cancer, Cartes d'Identité des Tumeurs program, Paris, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Benslimane-Ahmim Z, Heymann D, Dizier B, Lokajczyk A, Brion R, Laurendeau I, Bièche I, Smadja DM, Galy-Fauroux I, Colliec-Jouault S, Fischer AM, Boisson-Vidal C. Osteoprotegerin, a new actor in vasculogenesis, stimulates endothelial colony-forming cells properties. J Thromb Haemost 2011; 9:834-43. [PMID: 21255246 DOI: 10.1111/j.1538-7836.2011.04207.x] [Citation(s) in RCA: 45] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
BACKGROUND Osteoprotegerin (OPG), a soluble receptor of the tumour necrosis factor family, and its ligand, the receptor activator of nuclear factor-κB ligand (RANKL), are emerging as important regulators of vascular pathophysiology. OBJECTIVES We evaluated their effects on vasculogenesis induced by endothelial colony-forming cells (ECFC) and on neovessel formation in vivo. METHODS Effects of OPG and RANKL on in vitro angiogenesis were evaluated after ECFC incubation with OPG or RANKL (0-50 ng mL(-1)). Effects on microvessel formation were evaluated with an in vivo murin Matrigel plug assay. Vascularization was evaluated by measuring plug hemoglobin and vascular endothelial growth factor (VEGF)-R2 content 14 days after implantation. RESULTS We found that ECFC expressed OPG and RANK but not RANKL mRNA. Treatment of ECFC with VEGF or stromal cell-derived factor-1 (SDF-1) upregulated OPG mRNA expression. OPG stimulated ECFC migration (P < 0.05), chemotaxis (P < 0.05) and vascular cord formation on Matrigel(®) (P < 0.01). These effects were correlated with SDF-1 mRNA overexpression, which was 30-fold higher after 4 h of OPG stimulation (P < 0.01). OPG-mediated angiogenesis involved the MAPK signaling pathway as well as Akt or mTOR cascades. RANKL also showed pro-vasculogenic effects in vitro. OPG combined with FGF-2 promoted neovessel formation in vivo, whereas RANKL had no effect. CONCLUSIONS OPG induces ECFC activation and is a positive regulator of microvessel formation in vivo. Our results suggest that the OPG/RANK/RANKL axis may be involved in vasculogenesis and strongly support a modulatory role in tissue revascularization.
Collapse
|
35
|
Sinilnikova OM, Antoniou AC, Simard J, Healey S, Léoné M, Sinnett D, Spurdle AB, Beesley J, Chen X, Greene MH, Loud JT, Lejbkowicz F, Rennert G, Dishon S, Andrulis IL, Domchek SM, Nathanson KL, Manoukian S, Radice P, Konstantopoulou I, Blanco I, Laborde AL, Durán M, Osorio A, Benitez J, Hamann U, Hogervorst FBL, van Os TAM, Gille HJP, Peock S, Cook M, Luccarini C, Evans DG, Lalloo F, Eeles R, Pichert G, Davidson R, Cole T, Cook J, Paterson J, Brewer C, Hughes DJ, Coupier I, Giraud S, Coulet F, Colas C, Soubrier F, Rouleau E, Bièche I, Lidereau R, Demange L, Nogues C, Lynch HT, Schmutzler RK, Versmold B, Engel C, Meindl A, Arnold N, Sutter C, Deissler H, Schaefer D, Froster UG, Aittomäki K, Nevanlinna H, McGuffog L, Easton DF, Chenevix-Trench G, Stoppa-Lyonnet D. The TP53 Arg72Pro and MDM2 309G>T polymorphisms are not associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. Br J Cancer 2009; 101:1456-60. [PMID: 19707196 PMCID: PMC2768437 DOI: 10.1038/sj.bjc.6605279] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
Background: The TP53 pathway, in which TP53 and its negative regulator MDM2 are the central elements, has an important role in carcinogenesis, particularly in BRCA1- and BRCA2-mediated carcinogenesis. A single nucleotide polymorphism (SNP) in the promoter region of MDM2 (309T>G, rs2279744) and a coding SNP of TP53 (Arg72Pro, rs1042522) have been shown to be of functional significance. Methods: To investigate whether these SNPs modify breast cancer risk for BRCA1 and BRCA2 mutation carriers, we pooled genotype data on the TP53 Arg72Pro SNP in 7011 mutation carriers and on the MDM2 309T>G SNP in 2222 mutation carriers from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Data were analysed using a Cox proportional hazards model within a retrospective likelihood framework. Results: No association was found between these SNPs and breast cancer risk for BRCA1 (TP53: per-allele hazard ratio (HR)=1.01, 95% confidence interval (CI): 0.93–1.10, Ptrend=0.77; MDM2: HR=0.96, 95%CI: 0.84–1.09, Ptrend=0.54) or for BRCA2 mutation carriers (TP53: HR=0.99, 95%CI: 0.87–1.12, Ptrend=0.83; MDM2: HR=0.98, 95%CI: 0.80–1.21, Ptrend=0.88). We also evaluated the potential combined effects of both SNPs on breast cancer risk, however, none of their combined genotypes showed any evidence of association. Conclusion: There was no evidence that TP53 Arg72Pro or MDM2 309T>G, either singly or in combination, influence breast cancer risk in BRCA1 or BRCA2 mutation carriers.
Collapse
Affiliation(s)
- O M Sinilnikova
- Unité Mixte de Génétique Constitutionnelle des Cancers Fréquents, Hospices Civils de Lyon, Centre Léon Bérard, Lyon 69373, France.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
36
|
Abstract
Hepatitis C virus (HCV) is a major cause of chronic liver disease, with about 170 million people infected worldwide. Up to 70% of patients will have persistent infection after inoculation, making this disease a significant cause of morbidity and mortality. The severity of disease varies widely, from asymptomatic chronic infection to cirrhosis and hepatocellular carcinoma. Since the discovery of HCV, the treatment of hepatitis C has considerably improved. Recently, combination of pegylated interferons with ribavirin gives a response rate of about 55%. Treatment is indicated in patients with moderate or severe fibrosis. The tolerability of combination treatment is relatively poor, with a frequent flu-like syndrome and an impaired quality of life. In addition to viral and environmental behavioural factors, host genetic diversity is believed to contribute to the spectrum of clinical outcomes in HCV infection. The sequencing of the human genome, together with the development of high-throughput technologies that measure the function of the genome, have afforded unique opportunities to develop profiles that can distinguish, identify and classify discrete subsets of disease, predict the disease outcome or predict the response to treatment. This paper reviews the published literature on gene expression associated with HCV infection (HCV infection, fibrosis progression), and also according to response to treatment.
Collapse
Affiliation(s)
- T Asselah
- INSERM, U773, Centre de Recherche Bichat-Beaujon CRB3, Paris, France.
| | - I Bièche
- INSERM, U745, Université René Descartes, Paris, France,Service de Génétique Moléculaire, Hôpital Beaujon, Clichy, France
| | - A Sabbagh
- INSERM, U745, Université René Descartes, Paris, France,Service de Génétique Moléculaire, Hôpital Beaujon, Clichy, France
| | - P Bedossa
- Service d’Anatomie-Pathologie, Hôpital Beaujon, Clichy, France
| | - R Moreau
- INSERM, U773, Centre de Recherche Bichat-Beaujon CRB3, Paris, France,Université Denis Diderot-Paris 7, Site Bichat, France,Service d’hépatologie, Hôpital Beaujon, Clichy, France
| | - D Valla
- INSERM, U773, Centre de Recherche Bichat-Beaujon CRB3, Paris, France,Université Denis Diderot-Paris 7, Site Bichat, France,Service d’hépatologie, Hôpital Beaujon, Clichy, France
| | - M Vidaud
- INSERM, U745, Université René Descartes, Paris, France,Service de Génétique Moléculaire, Hôpital Beaujon, Clichy, France
| | - P Marcellin
- INSERM, U773, Centre de Recherche Bichat-Beaujon CRB3, Paris, France,Université Denis Diderot-Paris 7, Site Bichat, France,Service d’hépatologie, Hôpital Beaujon, Clichy, France
| |
Collapse
|
37
|
Rouleau E, Spyratos F, Dieumegard B, Guinebretière JM, Lidereau R, Bièche I. KRAS mutation status in colorectal cancer to predict response to EGFR targeted therapies: the need for a more precise definition. Br J Cancer 2009; 99:2100. [PMID: 19078954 PMCID: PMC2607232 DOI: 10.1038/sj.bjc.6604815] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022] Open
|
38
|
Maris C, Rorive S, Sandras F, D'Haene N, Sadeghi N, Bièche I, Vidaud M, Decaestecker C, Salmon I. Tenascin-C expression relates to clinicopathological features in pilocytic and diffuse astrocytomas. Neuropathol Appl Neurobiol 2008; 34:316-29. [DOI: 10.1111/j.1365-2990.2007.00898.x] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
|
39
|
Tozlu-Kara S, Roux V, Andrieu C, Vendrell J, Vacher S, Lazar V, Spyratos F, Tubiana-Hulin M, Cohen P, Dessen P, Lidereau R, Bièche I. Oligonucleotide microarray analysis of estrogen receptor alpha-positive postmenopausal breast carcinomas: identification of HRPAP20 and TIMELESS as outstanding candidate markers to predict the response to tamoxifen. J Mol Endocrinol 2007; 39:305-18. [PMID: 17909269 DOI: 10.1677/jme-07-0001] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
The estrogen receptor alpha (ER alpha) status of breast tumors is used to identify patients who may respond to endocrine agents such as tamoxifen. However, ER alpha status alone is not perfectly predictive, and there is a pressing need for more reliable markers of endocrine responsiveness. In this aim, we used a two-step strategy. We first screened genes of interest by a pangenomic 44 K oligonucleotide microarray in a series of ten ER alpha-positive tumors from five tamoxifen-treated postmenopausal patients who relapsed (distant metastasis) and five tamoxifen-treated postmenopausal patients who did not relapse, matched with respect to age, Scarff-Bloom-Richardson grade, lymph node status, and macroscopic tumor size. Genes of interest (n=24) were then investigated in an independent well-characterized series of ER alpha-positive unilateral invasive primary breast tumors from postmenopausal women who received tamoxifen alone as adjuvant hormone therapy after primary surgery. We identified four genes (HRPAP20, TIMELESS, PTPLB, and MGC29814) for which high mRNA levels were significantly associated with shorter relapse-free survival (log-rank test). We also showed that hormone-regulated proliferation-associated 20 kDa protein (HRPAP20) and TIMELESS are 17beta-estradiol-regulated in vitro and are ectopically expressed in OH-Tam-resistant cell lines. In conclusion, these findings point to HRPAP20 and TIMELESS as promising markers of tamoxifen resistance in women with ER alpha-positive breast tumors.
Collapse
Affiliation(s)
- S Tozlu-Kara
- Centre René Huguenin, FNCLCC, F-92210 St-Cloud, France
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
40
|
Smadja DM, Bièche I, Emmerich J, Aiach M, Gaussem P. PAR-1 activation has different effects on the angiogenic activity of endothelial progenitor cells derived from human adult and cord blood. J Thromb Haemost 2006; 4:2729-31. [PMID: 17100658 DOI: 10.1111/j.1538-7836.2006.02208.x] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
|
41
|
Di Benedetto M, Bièche I, Deshayes F, Vacher S, Nouet S, Collura V, Seitz I, Louis S, Pineau P, Amsellem-Ouazana D, Couraud PO, Strosberg AD, Stoppa-Lyonnet D, Lidereau R, Nahmias C. Structural organization and expression of human MTUS1, a candidate 8p22 tumor suppressor gene encoding a family of angiotensin II AT2 receptor-interacting proteins, ATIP. Gene 2006; 380:127-36. [PMID: 16887298 DOI: 10.1016/j.gene.2006.05.021] [Citation(s) in RCA: 63] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/27/2006] [Revised: 05/05/2006] [Accepted: 05/18/2006] [Indexed: 10/24/2022]
Abstract
The Mitochondrial Tumor suppressor 1 (MTUS1) gene is a newly identified candidate tumor suppressor gene at chromosomal position 8p22. We report here that MTUS1 encodes a family of proteins whose leader member (ATIP1) was previously isolated in our laboratory as a novel interacting partner of the angiotensin II AT2 receptor involved in growth inhibition (Nouet, JBC 279: 28989-97, 2004). The MTUS1 gene contains 17 coding exons distributed over 112 kb of genomic DNA. Alternative exon usage generates three major transcripts (ATIP1, ATIP3 and ATIP4), each showing different tissue distribution. ATIP polypeptides are identical in their carboxy-terminal region carrying four coiled-coil domains. In their amino-terminal portion, ATIP polypeptides exhibit distinct motifs for localisation in the cytosol, nucleus or cell membrane, suggesting that MTUS1 gene products may be involved in a variety of intracellular functions in an AT2-dependent and independent manner. ATIP1 is ubiquitous and highly expressed in the brain. ATIP3 is the major transcript in tissues (prostate, bladder, breast, ovary, colon) corresponding to cancer types with frequent loss of heterozygosity at 8p22. Interestingly, ATIP4 is a brain-specific transcript highly abundant in the cerebellum and fetal brain. High evolutionary conservation of ATIP amino-acid sequences suggests important biological roles for this new family of proteins in tumor suppression and/or brain function.
Collapse
Affiliation(s)
- M Di Benedetto
- Institut Cochin, Département de Biologie Cellulaire, Paris, F-75014, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
42
|
Asselah T, Bièche I, Laurendeau I, Paradis V, Saadoun D, Valla D, Bedossa P, Vidaud M, Marcellin P. O.139 Two types of histologically normal liver can have different gene expression patterns: The importance of an adequate normal tissue control in gene expression studies. J Clin Virol 2006. [DOI: 10.1016/s1386-6532(06)80133-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
43
|
Paradis V, Bièche I, Dargère D, Cazals-Hatem D, Laurendeau I, Saada V, Belghiti J, Bezeaud A, Vidaud M, Bedossa P, Valla DC. Quantitative gene expression in Budd-Chiari syndrome: a molecular approach to the pathogenesis of the disease. Gut 2005; 54:1776-81. [PMID: 16162682 PMCID: PMC1774794 DOI: 10.1136/gut.2005.065144] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
BACKGROUND Budd-Chiari syndrome (BCS) is associated with parenchymal changes leading to major architecture remodelling. In order to gain further insight into the pathogenesis of BCS, we investigated expression of a set of genes involved in the course of chronic liver diseases. METHODS Quantitative expression of 35 selected genes involved in extracellular matrix regulation, growth factors, and angiogenesis was investigated in 13 cases of BCS and compared with 10 normal livers and 13 cirrhosis cases by real time reverse transcription-polymerase chain reaction. Differential gene expression was considered significant for genes showing at least a twofold variation, with p < 0.05. RESULTS Expression of 14 genes was significantly increased in BCS versus normal liver, with the highest increase in superior cervical ganglion 10 (SCG10) gene. BCS cases were classified according to their evolution and morphological pattern as either acute or chronic in six and seven cases, respectively. Unsupervised hierarchical clustering of acute and chronic BCS cases on the basis of similarity in gene expression pattern led to distinction between the two groups. Expression of three genes was significantly different in acute versus chronic BCS (increase in matrix metalloproteinase 7 and SCG10, decrease in thrombospondin-1 for chronic BCS). Seventeen and 10 genes, mainly involved in extracellular matrix and vascular remodelling, were significantly deregulated in acute BCS versus normal liver and cirrhosis, respectively. CONCLUSION These results show that BCS cases display a specific gene expression profile that is different from that of normal liver and cirrhosis; the molecular configuration of BCS can be readily distinguished by its evolution and morphological pattern.
Collapse
Affiliation(s)
- V Paradis
- Service d'Anatomie Pathologique, Hôpital Beaujon, 110 bd du général Leclerc, 92118 Clichy Cedex, France.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
44
|
Olivier M, Langerød A, Carrieri P, Bergh J, Klaar S, Eyfjord J, Theillet C, Rodriguez C, Lidereau R, Bièche I, Varley J, Bignon Y, Uhrhammer N, Winqvist R, Jukkola-Vuorinen A, Niederacher D, Kato S, Ishioka C, Hainaut P, Børresen-Dale AL. Independent prognostic value of somatic TP53gene mutations in 1794 breast cancer patients. Breast Cancer Res 2005. [PMCID: PMC4233599 DOI: 10.1186/bcr1178] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
45
|
Girault I, Lidereau R, Bièche I. Trimodal GSTT1 and GSTM1 genotyping assay by real-time PCR. Int J Biol Markers 2005; 20:81-6. [PMID: 16011037] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/03/2023]
Abstract
The GSTT1 and GSTM1 genes are characterized by the existence of a GST*0 null allele responsible for a lack of enzyme activity, with the respective null genotypes GSTT1*0/0 and GSTM1*0/0. The three resulting genotypes (GSTs*1/1, *1/0 and *0/0) are associated with a trimodal distribution of glutathione-conjugator activity. Previous epidemiological studies have only evaluated the cancer risk associated with the GST null genotype relative to the two GST carrier genotypes (GSTs1*1/1 and *1/0). We developed GSTT1 and GSTM1 TaqMan real-time quantitative PCR assays to discriminate each of the three genotypes, with the albumin gene (ALB) as reference. The mean N(GSTT1*1/1) value was 1.0 (95% confidence interval 0.80-1.20). The mean N(GSTT1*1/0) value was 0.48 (95% CI 0.36-0.60). One (3.4%) of the 29 DNA samples yielded the GSTM1*1/1 genotype (N(GSTM1*1/1) = 1), a frequency in keeping with the Hardy-Weinberg distribution. The mean N(GSTM1*1/0) value was 0.50 (95% CI 0.42-0.58). All GSTT1*0/0 and GSTM1*0/0 samples yielded N(GST) values of 0 (Ct = 40); the frequencies of these genotypes (27.6% and 55.2%, respectively) were in keeping with published data. The GSTT1 and GSTM1 real-time PCR assays described here unambiguously discriminate each of the three existing genotypes which should be valuable for assessing the relative risk of cancer associated with each of the three GST genotypes.
Collapse
Affiliation(s)
- I Girault
- Laboratoire d'Oncogénétique, INSERM U735, Centre René Huguenin, St-Cloud, France
| | | | | |
Collapse
|
46
|
Becette V, Vignaud S, Régnier C, Labroquére M, Fourme E, Menet E, Bièche I, Spyratos F. Gene transcript assay by real-time RT-PCR in epithelial breast cancer cells selected by laser microdissection. Int J Biol Markers 2005; 19:100-8. [PMID: 15255541 DOI: 10.1177/172460080401900203] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
The cell type heterogeneity within clinical cancer tissue samples may affect the accuracy of gene expression analysis. In order to validate our laser microdissection (LMD) method using the Leica AS LMD system (LEICA Microsystems), we compared the mRNA levels of three major genes involved in breast cancer (ERalpha, PR, HER2), measured by means of real-time quantitative RT-PCR, in 5000 microdissected malignant epithelial cells and in corresponding bulk tumor homogenates from 14 patients. We also compared the mRNA level results to protein expression measured by immunohistochemistry (IHC) on the same tumors. For the three genes, significant correlations were found between mRNA results obtained on microdissected cells and IHC. Comparison between IHC and mRNA results obtained on microdissected cells and bulk tumors showed that in all cases microdissection enhanced the sensitivity of assessing target gene transcript levels and was essential for their accurate evaluation in heterogeneous tumors.
Collapse
Affiliation(s)
- V Becette
- Department de Pathologie, INSERM E0017, Centre René Huguenin, Saint-Cloud, France.
| | | | | | | | | | | | | | | |
Collapse
|
47
|
Barrois M, Bièche I, Mazoyer S, Champème MH, Bressac-de Paillerets B, Lidereau R. Real-time PCR-based gene dosage assay for detecting BRCA1 rearrangements in breast-ovarian cancer families. Clin Genet 2004; 65:131-6. [PMID: 14984472 DOI: 10.1111/j.0009-9163.2004.00200.x] [Citation(s) in RCA: 41] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
BRCA1 and BRCA2 germline mutations, mainly point mutations and other small alterations, are responsible for most hereditary cases of breast-ovarian cancer. However, the observed frequency of BRCA1 alterations is lower than that predicted by linkage analysis. Several large BRCA1 rearrangements have been identified with a variety of technical approaches in some families. We have developed a gene dosage assay based on real-time quantitative PCR and used it to extensively analyze 91 French families of breast-ovarian cancer in which no BRCA1 or BRCA2 point mutations was identified. This gene dosage method calculates the copy number of each BRCA1 exon to readily detect one, two, and three or more copies of BRCA1 target exons. In the series of 91 families at high risk of carrying BRCA1 mutations, we detected seven large rearrangements of the BRCA1 gene by using this real-time PCR approach. This simple, rapid, and semiautomated real-time quantitative polymerase chain reaction (PCR) assay is a promising alternative technique to Southern blot, bar code analysis on combed DNA, quantitative multiplex PCR of short fluorescent fragments, and cDNA length analysis for the detection of large rearrangements. Therefore, this technique should be considered as a powerful diagnostic method for breast/ovarian cancer susceptibility in clinical and research genetic surveys.
Collapse
Affiliation(s)
- M Barrois
- Service de Génétique, Institut Gustave Roussy, Villejuif, France
| | | | | | | | | | | |
Collapse
|
48
|
Cavé H, Acquaviva C, Bièche I, Brault D, de Fraipont F, Fina F, Loric S, Maisonneuve L, Namour F, Tuffery S. [RT-PCR in clinical diagnosis]. Ann Biol Clin (Paris) 2003; 61:635-44. [PMID: 14711604] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/27/2023]
Abstract
Application fields of RT-PCR (reverse transcription-polymerase chain reaction) in clinical diagnosis comprises the assessment of viral load for RNA viruses and the analysis of gene transcription products. RT-PCR is also helpful when large genes have to be sequenced. Developments of quantitative approaches using real-time PCR recently led to a major widening of RT-PCR applications in clinical diagnosis. However, RT reaction is delicate due to its lack of reproducibility and to RNA lability and frequent contamination by DNA. In some cases additional difficulties come from the need to obtain a specific amplification in the presence of homologous sequences which might be present in higher amounts than the sequence of interest. These caveats have to be taken into account, when designing the RT protocol, and when choosing PCR primers and internal and/or external references. This review is aimed at helping the experimental setup of a RT-PCR based assay according to the objectives.
Collapse
Affiliation(s)
- H Cavé
- Laboratoire de biochimie génétique, Fédération de génétique, Hôpital Robert Debré (AP-HP), 48, boulevard Sérurier, 75019 Paris.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
49
|
Bièche I, Girault I, Sabourin JC, Tozlu S, Driouch K, Vidaud M, Lidereau R. Prognostic value of maspin mRNA expression in ER alpha-positive postmenopausal breast carcinomas. Br J Cancer 2003; 88:863-70. [PMID: 12644823 PMCID: PMC2377080 DOI: 10.1038/sj.bjc.6600812] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023] Open
Abstract
Maspin, a member of the serpin family, has a role in cell migration, angiogenesis and apoptosis. Little is known of the clinical significance of maspin gene expression in human cancers. We developed a real-time quantitative RT-PCR assay to quantify the full range of maspin mRNA copy numbers in a series of 10 ER alpha-positive and 10 ER alpha-negative breast tumours. We observed a statistical link between low maspin mRNA levels and positive oestrogen status (P=0.0012). In consequence, to better assess the prognostic value of maspin gene expression in breast cancer, we then quantified maspin mRNA content in an additional independent well-defined cohort of 105 ER alpha-positive postmenopausal breast cancer patients treated with primary surgery followed by adjuvant tamoxifen alone. Maspin expression varied widely in tumour tissues (by nearly four orders of magnitude), being underexpressed in 33 out of 105 tumours (31.4%) and overexpressed in 24 out of 105 tumours (22.9%) relative to normal breast tissues. Immunohistochemical studies demonstrated that maspin protein was strictly expressed in myoepithelial cells of normal breast tissue and in tumour epithelial cells, exclusively in maspin-overexpressing tumours. Patients with tumours overexpressing the maspin gene had significantly shorter relapse-free survival after surgery than patients whose tumours normally expressed or underexpressed maspin (P=0.0011). The prognostic significance of maspin overexpression persisted in Cox multivariate regression analysis (P=0.0024). These findings show that the maspin mRNA level can have important prognostic significance in human breast cancer, and point to the maspin gene as a putative molecular predictor of hormone responsiveness in breast cancer.
Collapse
Affiliation(s)
- I Bièche
- Laboratoire d'Oncogénétique, INSERM E0017, 35 rue Dailly, Centre René Huguenin, St Cloud, France.
| | | | | | | | | | | | | |
Collapse
|
50
|
Girault I, Lerebours F, Tozlu S, Spyratos F, Tubiana-Hulin M, Lidereau R, Bièche I. Real-time reverse transcription PCR assay of CYP19 expression: application to a well-defined series of post-menopausal breast carcinomas. J Steroid Biochem Mol Biol 2002; 82:323-32. [PMID: 12589939 DOI: 10.1016/s0960-0760(02)00190-5] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
Aromatase, the product of the CYP19 gene, plays a key role in androgenic steroids transformation into estrogens from various hormonal sensitive tissues. Thus, in situ expression of CYP19 has been suggested to be involved in breast tumor growth especially in post-menopausal patients.We developed a real-time quantitative RT-PCR assay based on fluorescent TaqMan methodology to quantify total CYP19 gene expression at the mRNA level in breast tumors. This method, based on nucleic acid quantification in homogeneous solutions, has the potential to become a standard in terms of its sensitivity, wide dynamic range and high-throughput capacity. In a well-defined series of 107 post-menopausal breast tumor samples, relative CYP19 mRNA levels ranged from 1 to 131. Among the four major CYP19 exon I-spliced transcripts, designated I.a, I.b, I.c and I.d, mRNA levels of the latter three correlated positively with total CYP19 mRNA levels. In ER alpha-positive breast tumors, CYP19 and ER alpha mRNA levels correlated negatively with each other (P=0.0078, r=-0.266), while CYP19 and ER beta mRNA levels correlated positively (P=0.00012, r=+0.388). Patients with high CYP19 mRNA levels did not relapse more frequently or have shorter relapse-free survival than other patients. Finally, mRNA levels of IL6, a major CYP19 regulatory factor, were significantly higher in tumors strongly expressing CYP19 than in tumors weakly expressing CYP19 (P=0.018). In conclusion, CYP19 expression did not influence the outcome of post-menopausal patients with breast cancer.
Collapse
Affiliation(s)
- I Girault
- Laboratoire d'Oncogénétique, INSERM E0017, Centre René Huguenin, 35 rue Dailly, St-Cloud, F-92211 Paris, France
| | | | | | | | | | | | | |
Collapse
|